Detuned Anti-human serum albumin (HSA) antibodies

Bispecific, trispecific, and multispecific antibodies with detuned anti-HSA regions address stability and accessibility issues, enhancing therapeutic efficacy in autoimmune and inflammatory diseases by improving antibody activity at cellular synapses.

WO2026235748A1PCT designated stage Publication Date: 2026-11-12INDUPRO LABS +4
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/059982
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2025-12-16
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing antibody formats, such as traditional monoclonal antibodies, lack stability and effective accessibility to cellular synapses, limiting their therapeutic efficacy, particularly in treating autoimmune and inflammatory diseases.

Method used

Development of bispecific, trispecific, and multispecific antibodies with a detuned anti-Human Serum Albumin (HSA) antibody region and target-specific antibody regions, featuring reduced affinity to HSA through mutations, enhancing stability and accessibility to cellular synapses, thereby improving therapeutic activity.

Benefits of technology

The detuned anti-HSA antibody regions increase the stability and accessibility of these antibodies, leading to improved activity in treating autoimmune and inflammatory diseases, including Type 1 diabetes, rheumatoid arthritis, and graft-versus-host disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025059982_12112026_PF_FP_ABST
    Figure US2025059982_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are antibodies including a detuned anti-Human Serum Albumin (HSA) antibody region and at least a first target-specific antibody region.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 062460-505001WG

[0002] DETUNED ANTI-HUMAN SERUM ALBUMIN (HSA) ANTIBODIES CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U. S. Provisional Patent Application No. 63 / 799,757 filed May 5, 2025, the contents of which is incorporated by reference herein in its entirety.

[0004] INCORPORATION BY REFERENCE OF SEQUENCE LISTING

[0005] This application contains a Sequence Listing which has been submitted in. XML format via EFS-WEB and is hereby incorporated by reference in its entirety. Said. XML copy, created on December 16, 2025, is named 062460-505001WO.xml and is 280 kilobytes in size

[0006] BACKGROUND

[0007] Antibody formats having improved stability, including half-life, potentially provide critical therapeutics to those in need. The present disclosure provided such antibody formats.

[0008] SUMMARY

[0009] An aspect of the present disclosure is a bispecific antibody including a detuned anti-Human Serum Albumin (HSA) antibody region and a first target-specific antibody region.

[0010] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are each variable domains on a heavy chain (VHH).

[0011] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are serially linked.

[0012] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are serially linked via a linker, e.g., of SEQ ID NO: 60 to 64.

[0013] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region is N-terminal to the first target-specific antibody region.

[0014] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region is C-terminal to the first target-specific antibody region.

[0015] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region includes one or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.062460-505001WG In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region includes two or more mutations, three or more mutations, four or more mutations, five or more mutations, six or more mutations, seven or more mutations, eight or more mutations, nine or more mutations, or ten or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

[0016] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region includes a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49.

[0017] In embodiments, the detuned anti-HSA antibody region provides the bispecific antibody increased stability, e.g.,! life, when compared to an equivalent bispecific antibody lacking the detuned anti-HSA antibody region.

[0018] In embodiments, the detuned anti-HSA antibody region provides increased accessibility to a synapse between cells compared to an equivalent bispecific antibody comprising a wild type anti-HSA antibody region. In some cases, the increased accessibility to the synapse between cells improves activity of the bispecific antibody.

[0019] In embodiments, the present disclosure relates to a bispecific antibody, wherein the bispecific antibody includes two or more detuned anti-HSA antibody regions and / or two or more first targetspecific antibody regions.

[0020] In embodiments, the present disclosure relates to a bispecific antibody, wherein the bispecific antibody includes two detuned anti-HSA antibody regions and one first target-specific antibody region.

[0021] In embodiments, the present disclosure relates to a bispecific antibody, wherein the bispecific antibody includes one detuned anti-HSA antibody regions and two first target-specific antibody regions.

[0022] In embodiments, the present disclosure relates to a bispecific antibody, wherein the first targetspecific antibody region is directed to a cancer-related epitope.

[0023] In embodiments, the present disclosure relates to a bispecific antibody, wherein the first targetspecific antibody region is directed to an immune cell related epitope.

[0024] In embodiments, the present disclosure relates to a bispecific antibody, wherein the immune cell-related epitope is relevant to an autoimmune disease or an inflammatory disease.

[0025] In embodiments, the present disclosure relates to a bispecific antibody, wherein the autoimmune diseases or the inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU),062460-505001WG Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

[0026] In embodiments, the present disclosure relates to a bispecific antibody, wherein the autoimmune disease or the inflammatory disease is a graft-versus-host disease (GVHD).

[0027] Another aspect of the present disclosure is a trispecific antibody including a detuned HSA antibody region, a first target-specific antibody region, and a second target-specific antibody region.

[0028] A further aspect of the present disclosure is a multispecific antibody including a detuned HSA antibody region, a first target-specific antibody region, and a second target-specific antibody region, and an at least third target-specific antibody region.

[0029] An additional aspect of the present disclosure is a method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease, the method comprising contacting an effector cell with an effective amount of any herein disclosed antibody.

[0030] In an aspect, the present disclosure provides a method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD), the method comprising contacting an effector cell with an effective amount of any herein disclosed antibody.

[0031] In another aspect, the present disclosure provides a pharmaceutical composition comprising any herein disclosed antibody and a pharmaceutically acceptable carrier, diluent, or excipient.

[0032] the any herein

[0033] In yet another aspect, the present disclosure provides a polynucleotide or plurality of polynucleotides encoding any herein disclosed antibody.

[0034] An aspect of the present disclosure is a vector comprising any herein disclosed polynucleotide or plurality of polynucleotides.

[0035] Any aspect or embodiment described herein can be combined with any other aspect or embodiment as disclosed herein.

[0036] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A and FIG IB show illustrative antibody formats of the present disclosure.

[0037] FIG. 2 includes graphs showing potent PD-1 agonism by trispecific antibodies of the present disclosure in the Jurkat-PDl assay.

[0038] FIG. 3A and FIG.3B includes graphs showing T cell suppression by scVHH and Fc-fused trispecific antibodies by MLR with either human serum supplementation (FIG. 3A) or bovine serum supplementation (FIG. 3B).062460-505001WG FIG. 4 includes a graph showing data from scVHH constructs having the HSA- or the PD1 -specific VHH replaced with a VHH specific for Campylobacter jejuni flagella (CjeF), which has no binding activity in the experimental system.

[0039] FIG. 5 includes graphs showing receptor occupancy (RO) in cells that express PD-1 (left graphs) that lack PD-1 (right graphs).

[0040] FIG. 6 includes graphs comparing an scVHH of the present disclosure with the benchmark PD-1 agonist antibody in inhibition of inflammatory cytokines or chemokines.

[0041] FIG. 7A to FIG. 7D are graphs showing the effect of PD-1 tyrosine mutations on scVHHs or PD1 x CD2 KiH mvAbs of the present disclosure.

[0042] FIG. 8 is a graph showing that anti-HSA VHH variants, which comprise one or more mutations relative to a wild type anti-HSA VHH (“detuned anti-HSA VHHs”) and have lower affinities to HSA that correlate with those predicted by MOE software.

[0043] FIG. 9 A and FIG. 9B are graphs showing data with “HSA-detuned” scVHHs in a Jurkat / Raji assay in the presence of human serum..

[0044] FIG. 10A and FIG. 10B are graphs comparing an illustrative scVHH of the present disclosure to Rosnilimab.

[0045] FIG. HA and FIG. 11B are graphs showing that the “HSA-detuned” scVHH formats enable high potency in primary cell assays in the presence of human serum. FIG. 12A and FIG. 12B are graphs showing PD1 x CD2 multivalent antibodies suppress a Type 1 diabetes patient’s T cell response to pancreatic islet antigens.

[0046] FIG. 13A is a graph showing decreased expression of the cytokine IL-21 and FIG. 13B is a graph showing decreased expression of the chemokine CXCL13 in PBMCs obtained from a Rheumatoid arthritis (RA) patient when treated with PDlxCD2 multivalent antibodies of the present disclosure, compared to control.

[0047] FIG. 14A and FIG. 14B are graphs showing the activity of two PD1. CD2. HSA scVHH test articles and a benchmark PD-1 mAh in an FcyRIIIa-genotyped PBMC CEFX response assay.

[0048] FIG. 15 is a graph showing the stimulation of PD-1 / SHP2 association by the indicated PD1 x CD2 test articles in a Jurkat / Raji assay containing human serum.

[0049] FIG. 16A and FIG. 16B are graphs showing affinities ofPDl. CD2. HSA scVHH test articles for HSA and their potency in a Jurkat / Raji assay containing human serum, and the correlation between the two values.

[0050] FIG. 16C is a graph showing the activity of the indicated PD1. CD2. HSA scVHH test articles in a T cell + moDC MLR.062460-505001WG FIG. 17A and FIG. 17B are graphs showing the pharmacokinetics of scVHH test articles in mice expressing human serum albumin.

[0051] DETAILED DESCRIPTION

[0052] The present invention relates to antibody formats including a detuned anti-Human Serum Albumin (HSA) antibody region and, at least, a first target-specific antibody region.

[0053] The detuned anti-HSA antibody region includes one or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA. The detuned anti-HSA antibody region may include two or more mutations, three or more mutations, four or more mutations, five or more mutations, six or more mutations, seven or more mutations, eight or more mutations, nine or more mutations, or ten or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA. In some cases, the detuned anti-HSA antibody region includes a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49. The detuned anti-HSA antibody region provides the antibody increased stability, e.g., % life, when compared to an equivalent antibody lacking the detuned anti-HSA antibody region. In some cases, the detuned anti-HSA antibody region provides increased accessibility to a synapse between cells compared to an equivalent antibody comprising a wild type anti-HSA antibody region; the increased accessibility to the synapse between cells improves activity of the antibody.

[0054] The term “multivalent antibody” “multivalent antibodies” or “multivalent” or “multivalents” or “mvAb” or “mvAbs” as provided herein is used according to its conventional meaning well known in the art and refers to a multivalent recombinant protein capable of simultaneously binding to at least two different antigens, e.g., two different antigens (a “bispecific antibody”), three different antigens (a “trispecific antibody”) or four or more different antigens. In contrast to traditional monoclonal antibodies, multivalent antibodies, here bispecific antibodies, include two independently different antibody regions (i.e., an anti-HSA antibody region and an anti-PD-1 antibody region or an anti-CD2 antibody region). Binding of the multivalent antibody to an effector cell (e.g. T cell) may activate the effector cell or downregulate or inhibit immunomodulatory signals to the effector cell. In embodiments, binding of the multivalent antibody to the effector cell activates the effector cell. In embodiments, binding of the multivalent antibody to the effector cell modulates the effector cell. In some embodiments, the multivalent antibody which is a trispecific comprises three independently different antibody regions (i.e., an anti-HSA antibody region, an anti-PD-1 antibody region, and an anti-CD2 antibody region).062460-505001WG Bispecific Antibodies

[0055] An aspect of the present disclosure is a bispecific antibody including a detuned anti-Human Serum Albumin (HSA) antibody region and a first target-specific antibody region.

[0056] FIG. 1A (top three images) includes illustrative bispecific serially linked single variable domains on a heavy chain (VHH); as shown, the serially linked VHH (scVHH) comprise a plurality of VHH domains directed to a plurality of different antigens. In embodiments, the serially linked VHH lacks a constant domain, e.g., an Fc domain. In other embodiments, the serial linked VHH comprises a constant domain. Another term for a serially linked VHH is a single chain VHH or scVHH. In each instance of the bispecific antibodies shown in FIG. 1A, a detuned anti-HSA VHH domain is present and a first target-specific antibody region is present; the first target-specific antibody region can be the binding domain for any currently known antibody.

[0057] The term “bispecific antibody” “bispecific antibodies” or “bispecific” or “bispecifics” or “bsAb” or “bsAbs” as provided herein is used according to its conventional meaning well known in the art and refers to a bispecific recombinant protein capable of simultaneously binding to two different antigens. In contrast to traditional monoclonal antibodies, bispecific antibodies include two independently different antibody regions (i.e., a detuned anti-HSA antibody region and first targetspecific antibody region). Binding of the bispecific antibody to an effector cell (e g. T cell) may activate the effector cell or downregulate or inhibit immunomodulatory signals to the effector cell. In embodiments, binding of the bispecific antibody to the effector cell activates the effector cell. In embodiments, binding of the bispecific antibody to the effector cell modulates the effector cell.

[0058] An “antibody region” as provided herein refers to a monovalent or multivalent protein moiety that forms part of the bi specific antibody provided herein including embodiments thereof and that can recognize and bind an antigen (epitope). The antibody region provided herein may be a single variable domain on a heavy chain (VHH). An antibody region comprises a sufficient number of, e.g., three, complementarity determining regions (CDRs) that permit recognition and binding of the target epitope.

[0059] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are each variable domains on a heavy chain (VHH).

[0060] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are serially linked.062460-505001WG In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are serially linked via a linker, e.g., of SEQ ID NO: 60 to 64.

[0061] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region is N-terminal to the first target-specific antibody region.

[0062] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region is C-terminal to the first target-specific antibody region.

[0063] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region includes one or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

[0064] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region includes two or more mutations, three or more mutations, four or more mutations, five or more mutations, six or more mutations, seven or more mutations, eight or more mutations, nine or more mutations, or ten or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

[0065] In embodiments, the present disclosure relates to a bispecific antibody, wherein the detuned anti-HSA antibody region includes a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49.

[0066] In embodiments, the detuned anti-HSA antibody region provides the bispecific antibody increased stability, e.g., ’A life, when compared to an equivalent bispecific antibody lacking the detuned anti-HSA antibody region.

[0067] In embodiments, the detuned anti-HSA antibody region provides increased accessibility to a synapse between cells compared to an equivalent bispecific antibody comprising a wild type anti-HSA antibody region. In some cases, the increased accessibility to the synapse between cells improves activity of the bispecific antibody.

[0068] In embodiments, the present disclosure relates to a bispecific antibody, wherein the bispecific antibody includes two or more detuned anti-HSA antibody regions and / or two or more first targetspecific antibody regions.

[0069] In embodiments, the present disclosure relates to a bispecific antibody, wherein the bispecific antibody includes two detuned anti-HSA antibody regions and one first target-specific antibody region.062460-505001WG In embodiments, the present disclosure relates to a bispecific antibody, wherein the bispecific antibody includes one detuned anti-HSA antibody regions and two first target-specific antibody regions.

[0070] In embodiments, the bispecific antibodies of the present disclosure comprise Fc regions. Some illustrative antibodies comprise Fc regions having either a knob or a hole. In other cases, multivalent antibodies comprise Fc regions lacking a knob and a hole. Shown in FIG. IB are illustrative serially linked single variable domains on a heavy chain (VHH); as shown, the serially linked VHH comprise a plurality of VHH domain directed to a plurality of different antigens. In embodiments, the serially linked VHH lacks a constant domain, e.g., an Fc domain. In other embodiments, the serial linked VHH comprises a constant domain. FIG. 1H shows that a serial linked VHH has an AAA or a constant region (exemplified there as His-TEV-Fc); however, a serial linked VHH can have both an AAA and a constant region. Another term for a serially linked VHH is a single chain VHH or scVHH. FIG. 1H also shows illustrative scVHH which include an Fc domain, which are embodiments having a C-terminal “His-TEV-Fc”. Any of the herein disclosed multivalent antibodies may further comprise a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 57 and a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 58 or 59.

[0071] In embodiments, the present disclosure relates to a bispecific antibody, wherein the first targetspecific antibody region is directed to a cancer-related epitope.

[0072] In embodiments, the present disclosure relates to a bispecific antibody, wherein the first targetspecific antibody region is directed to an immune cell related epitope.

[0073] In embodiments, the present disclosure relates to a bispecific antibody, wherein the immune cell-related epitope is relevant to an autoimmune disease or an inflammatory disease.

[0074] In embodiments, the present disclosure relates to a bispecific antibody, wherein the autoimmune diseases or the inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

[0075] In embodiments, the present disclosure relates to a bispecific antibody, wherein the autoimmune disease or the inflammatory disease is a graft-versus-host disease (GVHD).

[0076] Trispecific Antibodies

[0077] Another aspect of the present disclosure is a trispecific antibody including a detuned HSA antibody region, a first target-specific antibody region, and a second target-specific antibody region.062460-505001WG FIG. 1A (images four to nine) and FIG. IB includes illustrative trispecific serially linked single variable domains on a heavy chain (VHH); as shown, the serially linked VHH (scVHH) comprise a plurality of VHH domains directed to a plurality of different antigens. In embodiments, the serially linked VHH lacks a constant domain, e.g., an Fc domain. Another term for a serially linked VHH is a single chain VHH or scVHH. In each instance of the trispecific antibodies shown in FIG.

[0078] 1A and FIG. IB, a detuned anti-HSA VHH domain is present and a first target-specific antibody region is present and a second target-specific antibody region is present; the first target-specific antibody region can be the binding domain for any currently known antibody and the second targetspecific antibody region can be the binding domain for any currently known antibody.

[0079] In embodiments, the trispecific antibodies of the present disclosure comprise Fc regions. Some illustrative antibodies comprise Fc regions having either a knob or a hole. In other cases, trispecific antibodies comprise Fc regions lacking a knob and a hole. Shown in FIG. IB are illustrative serially linked single variable domains on a heavy chain (VHH); as shown, the serially linked VHH comprise a plurality of VHH domain directed to a plurality of different antigens. In embodiments, the serially linked VHH lacks a constant domain, e g., an Fc domain. In other embodiments, the serial linked VHH comprises a constant domain. FIG. 1H shows that a serial linked VHH has an AAA or a constant region (exemplified there as His-TEV-Fc); however, a serial linked VHH can have both an AAA and a constant region. Another term for a serially linked VHH is a single chain VHH or scVHH. FIG. 1H also shows illustrative scVHH which include an Fc domain, which are embodiments having a C-terminal “His-TEV-Fc”. Any of the herein disclosed trispecific antibodies may further comprise a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 57 and a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 58 or 59.

[0080] The term “trispecific antibody” “trispecific antibodies” or “trispecific” or “trispecifics” as provided herein is used according to its conventional meaning well known in the art and refers to a trispecific recombinant protein capable of simultaneously binding to three different antigens. In contrast to traditional monoclonal antibodies, trispecific antibodies include three independently different antibody regions (i.e., a detuned anti-HSA antibody region, a first target-specific antibody region, and a second target-specific antibody region). Binding of the tri specific antibody to an effector cell (e.g. T cell) may activate the effector cell or downregulate or inhibit immunomodulatory signals to the effector cell. In embodiments, binding of the trispecific antibody to the effector cell activates the effector cell. In embodiments, binding of the trispecific antibody to the effector cell modulates the effector cell.062460-505001WG An “antibody region” as provided herein refers to a monovalent or multivalent protein moiety that forms part of the trispecific antibody provided herein including embodiments thereof and that can recognize and bind an antigen (epitope). The antibody region provided herein may be a single variable domain on a heavy chain (VHH). An antibody region comprises a sufficient number of, e.g., three, complementarity determining regions (CDRs) that permit recognition and binding of the target epitope.

[0081] In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region the first target-specific antibody region, and the second target-specific antibody region are each variable domains on a heavy chain (VHH).

[0082] In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region, the first target-specific antibody region, and the second target-specific antibody region are serially linked.

[0083] In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are serially linked via a linker.

[0084] In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region and the second target-specific antibody region are serially linked via a linker.

[0085] In embodiments, the present disclosure relates to a trispecific antibody, wherein the first targetspecific antibody region and the second target-specific antibody region are serially linked via a linker.

[0086] In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region is C-terminal to the first target-specific antibody region and / or to the second target- specific antibody region.

[0087] In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region is N-terminal to the first target-specific antibody region and / or to the second target- specific antibody region.

[0088] In embodiments, the present disclosure relates to a trispecific antibody, wherein the first targetspecific antibody region is N-terminal to the to the second target-specific antibody region.

[0089] In embodiments, the present disclosure relates to a trispecific antibody, wherein the first targetspecific antibody region is C-terminal to the to the second target-specific antibody region.

[0090] In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region includes one or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.062460-505001WG In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region includes two or more mutations, three or more mutations, four or more mutations, five or more mutations, six or more mutations, seven or more mutations, eight or more mutations, nine or more mutations, or ten or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

[0091] In embodiments, the present disclosure relates to a trispecific antibody, wherein the detuned anti-HSA antibody region includes a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49.

[0092] In embodiments, the detuned anti-HSA antibody region provides the trispecific antibody increased stability, e.g.,! life, when compared to an equivalent trispecific antibody lacking the detuned anti-HSA antibody region.

[0093] In embodiments, the detuned anti-HSA antibody region provides increased accessibility to a synapse between cells compared to an equivalent trispecific antibody comprising a wild type anti-HSA antibody region. In some cases, the increased accessibility to the synapse between cells improves activity of the trispecific antibody.

[0094] In embodiments, the present disclosure relates to a trispecific antibody, wherein the trispecific antibody includes two or more detuned anti-HSA antibody regions and / or two or more first targetspecific antibody regions and / or two or more second target-specific antibody regions.

[0095] In embodiments, the present disclosure relates to a trispecific antibody, wherein the trispecific antibody includes two detuned anti-HSA antibody regions and one first target-specific antibody region and one second target-specific antibody region.

[0096] In embodiments, the present disclosure relates to a trispecific antibody, wherein the trispecific antibody includes one detuned anti-HSA antibody regions and one first target-specific antibody region and two second target-specific antibody regions.

[0097] In embodiments, the present disclosure relates to a trispecific antibody, wherein the trispecific antibody includes one detuned anti-HSA antibody regions and two first target-specific antibody region and two second target-specific antibody regions.

[0098] In embodiments, the present disclosure relates to a trispecific antibody, wherein the trispecific antibody includes two detuned anti-HSA antibody regions and two first target-specific antibody region and one second target-specific antibody regions.

[0099] In embodiments, the present disclosure relates to a trispecific antibody, wherein the first targetspecific antibody region and / or the second target-specific antibody region is directed to an immune cell related epitope.062460-505001WG In embodiments, the present disclosure relates to a trispecific antibody, wherein the immune cell-related epitope is relevant to an autoimmune disease or an inflammatory disease.

[0100] In embodiments, the present disclosure relates to a trispecific antibody, wherein the autoimmune diseases or the inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

[0101] In embodiments, the present disclosure relates to a trispecific antibody, wherein the autoimmune disease or the inflammatory disease is a graft-versus-host disease (GVHD).

[0102] In embodiments, the present disclosure relates to a trispecific antibody, wherein the first targetspecific antibody region is directed to a cancer-related epitope and / or the second target-specific antibody region is directed to a cancer-related epitope.

[0103] In embodiments, the present disclosure relates to a trispecific antibody, wherein the first targetspecific antibody region binds to an antigen expressed by a cancer cell and the second target-specific antibody region binds to antigen expressed by the cancer cell.

[0104] In embodiments, the present disclosure relates to a trispecific antibody, wherein the first targetspecific antibody region binds to an antigen expressed by a cancer cell and the second target-specific antibody region binds to an antigen expressed by an effector cell.

[0105] In embodiments, the present disclosure relates to a trispecific antibody, wherein the first targetspecific antibody region binds to an antigen expressed by an effector cell and the second targetspecific antibody region binds to an antigen expressed by the effector cell.

[0106] In embodiments, the present disclosure relates to a trispecific antibody, wherein the effector cell is a CD8+ T cell (e.g., a CD8+ CD4- T cell), a CD4+ T cell (e.g., a CD8- CD4+ T cell), a gamma delta (yb) T cell, an invariant T cell, a natural killer (NK) cell, an invariant natural killer cell (iNK cell), an invariant natural killer T cell (iNKT cell), or a macrophage.

[0107] In embodiments, the present disclosure relates to a trispecific antibody, wherein the effector cell is a T cell.

[0108] In embodiments, the present disclosure relates to a trispecific antibody, wherein the T cell is a CD4+ T cell or a CD8+ T cell.

[0109] In embodiments, the present disclosure relates to a trispecific antibody, wherein binding of the trispecific antibody to antigens on the effector cell promotes recruitment of protein complexes to an immunological synapse.062460-505001WG Mulitspecific Antibodies

[0110] A further aspect of the present disclosure is a multispecific antibody including a detuned HSA antibody region, a first target-specific antibody region, and a second target-specific antibody region, and an at least third target-specific antibody region, e.g., a third, a fourth, a fifth, a sixth, or a greater numbered target-specific antibody region.

[0111] FIG. 1A (bottom six images) includes illustrative multispecific serially linked single variable domains on a heavy chain (VHH); as shown, the serially linked VHH (scVHH) comprise a plurality of VHH domains directed to a plurality of different antigens. In embodiments, the serially linked VHH lacks a constant domain, e.g., an Fc domain. Another term for a serially linked VHH is a single chain VHH or scVHH. In each instance of the multispecific antibodies shown in FIG. 1A, a detuned anti-HSA VHH domain is present and a first target-specific antibody region is present, a second targetspecific antibody region is present, and a third target-specific antibody region is present; the first target-specific antibody region can be the binding domain for any currently known antibody, the second target-specific antibody region can be the binding domain for any currently known antibody, and the third target-specific antibody region can be the binding domain for any currently known antibody.

[0112] In embodiments, the multispecific antibodies of the present disclosure comprise Fc regions. Some illustrative antibodies comprise Fc regions having either a knob or a hole. In other cases, multispecific antibodies comprise Fc regions lacking a knob and a hole. Shown in FIG. IB are illustrative serially linked single variable domains on a heavy chain (VHH); as shown, the serially linked VHH comprise a plurality of VHH domain directed to a plurality of different antigens. In embodiments, the serially linked VHH lacks a constant domain, e.g., an Fc domain. In other embodiments, the serial linked VHH comprises a constant domain. FIG. 1H shows that a serial linked VHH has an AAA or a constant region (exemplified there as His-TEV-Fc); however, a serial linked VHH can have both an AAA and a constant region. Another term for a serially linked VHH is a single chain VHH or scVHH. FIG. 1H also shows illustrative scVHH which include an Fc domain, which are embodiments having a C-terminal “His-TEV-Fc”. Any of the herein disclosed multispecific antibodies may further comprise a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 57 and a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 58 or 59.

[0113] The term “multispecific antibody” “multi specific antibodies” or “multi specific” or “multispecifics” as provided herein is used according to its conventional meaning well known in the art and refers to a multispecific recombinant protein capable of simultaneously binding to more than062460-505001WG three different antigens. In contrast to traditional monoclonal antibodies, multispecific antibodies include four or more independently different antibody regions (i.e., a detuned anti-HSA antibody region, a first target-specific antibody region, a second target-specific antibody region, and an at least third target-specific antibody region). Binding of the multispecific antibody to an effector cell (e.g. T cell) may activate the effector cell or downregulate or inhibit immunomodulatory signals to the effector cell. In embodiments, binding of the multi specific antibody to the effector cell activates the effector cell. In embodiments, binding of the multispecific antibody to the effector cell modulates the effector cell.

[0114] An “antibody region” as provided herein refers to a monovalent or multivalent protein moiety that forms part of the multispecific antibody provided herein including embodiments thereof and that can recognize and bind an antigen (epitope). The antibody region provided herein may be a single variable domain on a heavy chain (VHH). An antibody region comprises a sufficient number of, e.g., three, complementarity determining regions (CDRs) that permit recognition and binding of the target epitope.

[0115] In embodiments, the present disclosure relates to a multispecific antibody, wherein the detuned anti-HSA antibody region the first target-specific antibody region, the second target-specific antibody region, and the at least third target-specific antibody region are each variable domains on a heavy chain (VHH).

[0116] In embodiments, the present disclosure relates to a multispecific antibody, wherein the detuned anti-HSA antibody region, the first target-specific antibody region, the second target-specific antibody region, and the at least third target specific antibody region are serially linked.

[0117] In embodiments, the present disclosure relates to a multispecific antibody, wherein the detuned anti-HSA antibody region, the first target-specific antibody region, the second target-specific antibody region, and / or the at least third target specific antibody region are serially linked via a linker.

[0118] In embodiments, the present disclosure relates to a multispecific antibody, wherein the detuned anti-HSA antibody region is C-terminal to the first target-specific antibody region, to the second target- specific antibody region, and / or the at least third target specific antibody region.

[0119] In embodiments, the present disclosure relates to a multispecific antibody, wherein the detuned anti-HSA antibody region is N-terminal to the first target-specific antibody region, to the second target- specific antibody region, and / or the at least third target specific antibody region.

[0120] In embodiments, the present disclosure relates to a multispecific antibody, wherein the detuned anti-HSA antibody region includes one or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.062460-505001WG In embodiments, the present disclosure relates to a multispecific antibody, wherein the detuned anti-HSA antibody region includes two or more mutations, three or more mutations, four or more mutations, five or more mutations, six or more mutations, seven or more mutations, eight or more mutations, nine or more mutations, or ten or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

[0121] In embodiments, the present disclosure relates to a multispecific antibody, wherein the detuned anti-HSA antibody region includes a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49.

[0122] In embodiments, the detuned anti-HSA antibody region provides the multispecific antibody increased stability, e.g., ’A life, when compared to an equivalent multispecific antibody lacking the detuned anti-HSA antibody region.

[0123] In embodiments, the detuned anti-HSA antibody region provides increased accessibility to a synapse between cells compared to an equivalent multispecific antibody comprising a wild type anti-HSA antibody region. In some cases, the increased accessibility to the synapse between cells improves activity of the multispecific antibody.

[0124] In embodiments, the present disclosure relates to a multispecific antibody, wherein the multispecific antibody includes two or more detuned anti-HSA antibody regions and / or two or more first target-specific antibody regions and / or two or more second target-specific antibody regions and / or two or more at least third second target-specific antibody regions.

[0125] In embodiments, the present disclosure relates to a multispecific antibody, wherein the first target-specific antibody region and / or the second target-specific antibody region is directed to an immune cell related epitope.

[0126] In embodiments, the present disclosure relates to a multispecific antibody, wherein the immune cell-related epitope is relevant to an autoimmune disease or an inflammatory disease.

[0127] In embodiments, the present disclosure relates to a multispecific antibody, wherein the autoimmune diseases or the inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

[0128] In embodiments, the present disclosure relates to a multispecific antibody, wherein the autoimmune disease or the inflammatory disease is a graft-versus-host disease (GVHD).062460-505001WG In embodiments, the present disclosure relates to a multispecific antibody, wherein the first target-specific antibody region is directed to a cancer-related epitope and / or the second target-specific antibody region is directed to a cancer-related epitope.

[0129] In embodiments, the present disclosure relates to a multispecific antibody, wherein the first target-specific antibody region binds to an antigen expressed by a cancer cell and / or the second targetspecific antibody region binds to antigen expressed by the cancer cell and / or the at least third targetspecific antibody region binds to antigen expressed by the cancer cell.

[0130] In embodiments, the present disclosure relates to a multispecific antibody, wherein the first target- specific antibody region binds to an antigen expressed by a cancer cell or an effector cell and / or the second target-specific antibody region binds to antigen expressed by the cancer cell or the effector cell and / or the at least third target-specific antibody region binds to antigen expressed by the a cancer cell or the effector cell.

[0131] In embodiments, the present disclosure relates to a multispecific antibody, wherein the first target- specific antibody region binds to an antigen expressed by an effector cell and the second targetspecific antibody region binds to an antigen expressed by the effector cell.

[0132] In embodiments, the present disclosure relates to a multispecific antibody, wherein the effector cell is a CD8+ T cell (e g., a CD8+ CD4- T cell), a CD4+ T cell (e.g., a CD8- CD4+ T cell), a gamma delta (y5) T cell, an invariant T cell, a natural killer (NK) cell, an invariant natural killer cell (iNK cell), an invariant natural killer T cell (iNKT cell), or a macrophage.

[0133] In embodiments, the present disclosure relates to a multispecific antibody, wherein the effector cell is a T cell.

[0134] In embodiments, the present disclosure relates to a multispecific antibody, wherein the T cell is a CD4+ T cell or a CD8+ T cell.

[0135] In embodiments, the present disclosure relates to a multispecific antibody, wherein binding of the multispecific antibody to antigens on the effector cell promotes recruitment of protein complexes to an immunological synapse.

[0136] Detuned anti-HSA antibody regions

[0137] Each of the herein-disclosed antibodies comprises a detuned anti-HSA antibody region which includes a sequence that is at least 90% identical (e g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49.062460-505001WG Table 1: Illustrative HSA VHH Sequences

[0138]

[0139] 062460-505001WG

[0140]

[0141] 062460-505001WG

[0142]

[0143] An illustrative VHH capable of binding HSA is shown in Table 1 and comprises a sequence at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 1. In some cases, the wild type anti-HSA VHH has the sequence of SEQ ID NO: 1. Illustrative detuned anti-HSA VHH domains having reduced capacity for binding HSA due to one or more mutations relative to a wild type anti- HSA VHH, are shown in Table 1 and comprises a sequence at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49, e g., 19, 38, and 44.

[0144] In embodiments, a herein disclosed VHH, plurality of CDRs (i.e., three heavy chain CDRs or three heavy chain CDRs with three light CDRs), VL, VH, Fab, scFV, or a combination thereof may be used as a monospecific antibody, i.e., the antibody only binds to one antigen. A skilled artisan can determine the CDRs for a given sequence (e.g., from Table 1) by using well-known online tools, e.g.,062460-505001WG IMGT / V-QUEST & DomainGapAlign, GenSmart™ Variable Domain Sequence Analyzer (by GenScript), CDR Analyzer, TransNexus CDRAnalyzer, GL’s CDR Analysis System, SolarWinds VoIP & Network Quality Manager (VNQM), Sourcetable, CDAMS (CDR- Analysis), C5 CDR Analyzer, NetVizuraNetFlow Analyzer, MSAB XAMN, PenLink PLX, Paraben E3: DS, Open-source CDRA, or Nuix Investigate. Accordingly, the CDRs for any herein-disclosed HSA binding sequence can be readily determined and is contemplated as part of the present disclosure.

[0145] In embodiments an anti-HSA region comprises SEQ ID NO: 226 (GFTFSSFG), SEQ ID NO: 227 (ISGSGSDT), and SEQ ID NO: 228 (TIGGGLSR) respectively.

[0146] In embodiments an anti-HSA region comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) comprising SEQ ID NO: 229 (GFTFRSFG), SEQ ID NO: 230 (ISGSGSDT), and SEQ ID NO: 231 (TISGSLSR) respectively.

[0147] In embodiments an anti-HSA region comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) comprising SEQ ID NO: 232 (GFTFRSFG), SEQ ID NO: 233 (ISGSGSDT), and SEQ ID NO: 234 (TIGGVLSR) respectively.

[0148] In embodiments an anti-HSA region comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) comprising SEQ ID NO: 235 (GFTFSSFG), SEQ ID NO: 236 (ISGSGSDT), and SEQ ID NO: 237 (GGGLSR) respectively.

[0149] Any of the herein disclosed multivalent antibodies may further comprise a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 57 and a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 58 or 59.

[0150] In embodiments, the multivalent antibody includes a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to a sequence shown in Table 2.

[0151] Some of the Fc regions comprise “knob” or “hole” motifs. In some cases, the Fc region lacks knob” and “hole” motifs.

[0152] Table 2 Constant Regions

[0153]

[0154] 062460-505001WG

[0155]

[0156] In Table 2, “LALAPG” refers to a set of three mutations: (1) L -> A, (2) L -> A, and (3) P -> G. In Table 2, the term “FE”

[0157] SEQ ID 56 is a light chain (kappa) sequence, not a heavy chain (Fc-containing) sequence; however, for simplicity, in this disclosure, we are referring to it as an Fc sequence.062460-505001WG Linkers and Additional Sequences

[0158] Any antibody domain (e.g., VHH domains) in a herein-disclosed antibody may be linked by a polypeptide linker. Illustrative linkers are shown in Table 3. Multiple copies of a linker may be linked; for example, a ten-amino acid linker may be used which comprises two linked copies of the GS5 linker. An antibody of the present disclosure may include more than one type of linker; for example a linker between the first VHH and the second VHH may be the GS5 linker and the linker between the second VHH and the third VHH may be the GS9 linker.

[0159] Table 3:

[0160]

[0161] Methods

[0162] An aspect of the present disclosure is a method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease, the method comprising contacting an effector cell with an effective amount of any herein disclosed antibody.

[0163] An aspect of the present disclosure is a method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject in need thereof, the method comprising contacting an effector cell with an effective amount of any herein disclosed antibody. In some cases, the effector cell is in vitro, ex vivo, or in vivo.

[0164] An aspect of the present disclosure is a method of reducing the severity of an autoimmune disease or inflammatory disease in a subject, the method comprising administering to the subject an effective amount of any herein disclosed antibody.

[0165] In embodiments, the autoimmune diseases or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).062460-505001WG An aspect of the present disclosure is a method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD), the method comprising contacting an effector cell with an effective amount of any herein disclosed antibody.

[0166] An aspect of the present disclosure is a method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject in need thereof, the method comprising contacting an effector cell with an effective amount of any herein disclosed antibody. In some cases, the effector cell is in vitro, ex vivo, or in vivo.

[0167] An aspect of the present disclosure is a method for treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject an effective amount of any herein disclosed antibody.

[0168] In embodiments, the method further comprises administering to the subject an effective amount of an immunomodulatory drug, e.g., a checkpoint inhibitor, adoptive T cell therapy, monoclonal antibody therapy, corticosteroid, tumor necrosis factor inhibitor, interleukin-1 (IL-1) inhibitor, interleukin-6 (IL-6) inhibitor, T cell inhibitor, B-cell inhibitor, or Janus Kinase inhibitor. In some cases, the immunomodulatory drug is an immunosuppressant. In some cases, the method further comprises administering an effective amount of a standard of care therapy.

[0169] Pharmaceutical Compositions

[0170] An aspect of the present disclosure is a pharmaceutical composition comprising any herein disclosed antibody and a pharmaceutically acceptable carrier, diluent, or excipient.

[0171] In embodiments, the pharmaceutical composition is for use as a medicament in the treatment of an autoimmune disease or inflammatory disease or in the treatment of a graft-versus-host disease (GVHD).

[0172] An aspect of the present disclosure is a method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject in need thereof, the method comprising administering to the subject an effective amount of any herein disclosed pharmaceutical composition.

[0173] In embodiments, the autoimmune diseases or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

[0174] An aspect of the present disclosure is a method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject an effective amount of any herein disclosed pharmaceutical composition.062460-505001WG In embodiments, the method further comprises administering to the subject an effective amount of an immunomodulatory drug, e.g., a checkpoint inhibitor, adoptive T cell therapy, monoclonal antibody therapy, corticosteroid, tumor necrosis factor inhibitor, interleukin-1 (IL-1) inhibitor, interleukin-6 (IL-6) inhibitor, T cell inhibitor, B-cell inhibitor, or Janus Kinase inhibitor. In some cases, the immunomodulatory drug is an immunosuppressant. In some cases, the method further comprises administering an effective amount of a standard of care therapy.

[0175] Polynucleotides

[0176] An aspect of the present disclosure is a polynucleotide or plurality of polynucleotides encoding any herein disclosed antibody.

[0177] An aspect of the present disclosure is a vector comprising any herein disclosed polynucleotide or plurality of polynucleotides.

[0178] Definitions

[0179] Prior to setting forth this disclosure in more detail, it may be helpful to an understanding thereof to provide definitions of certain terms to be used herein.

[0180] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of particular embodiments, preferred embodiments of compositions, methods and materials are described herein. For the purposes of the present disclosure, the following terms are defined below. Additional definitions are set forth throughout this disclosure.

[0181] The articles “a,” “an,” and “the” are used herein to refer to one or to more than one (i.e., to at least one, or to one or more) of the grammatical object of the article. By way of example, “an element” means one element or one or more elements.

[0182] The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives.

[0183] The term “and / or” should be understood to mean either one, or both of the alternatives.

[0184] Throughout this specification, unless the context requires otherwise, the words “comprise”, “comprises” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. By “consisting of’ is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of’ indicates that the listed elements are required or062460-505001WG mandatory, and that no other elements may be present. By “consisting essentially of’ is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of’ indicates that the listed elements are required or mandatory, but that no other elements are present that materially affect the activity or action of the listed elements.

[0185] Reference throughout this specification to “one embodiment,” “an embodiment,” “a particular embodiment,” “a related embodiment,” “a certain embodiment,” “an additional embodiment,” or “a further embodiment” or combinations thereof means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. It is also understood that the positive recitation of a feature in one embodiment, serves as a basis for excluding the feature in a particular embodiment.

[0186] As used herein, the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by as much as 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. In one embodiment, the term “about” or “approximately” refers a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length ± 15%, ± 10%, ± 9%, ± 8%, ± 7%, ± 6%, ± 5%, ± 4%, ± 3%, ± 2%, or ± 1% about a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length.

[0187] In the present description, any value range, e.g., concentration range, percentage range, or ratio range, or integer range and the like, is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. The term “about”, when immediately preceding a number or numeral, means that the number or numeral ranges plus or minus 10%.

[0188] The term “increased” or “enhanced” amount of a physiological response, e.g., electrophysiological activity or cellular activity, is typically a “statistically significant” amount, and may include an increase that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1, e.g., 1.5, 1.6, 1.7.

[0189] 1.8, etc.) the level of activity in an untreated cell.062460-505001WG The term “decrease” or “reduced” amount of a physiological response, e.g., electrophysiological activity or cellular activity, is typically a “statistically significant” amount, and may include an decrease that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g., 500, 1000 times) (including all integers and decimal points in between and above 1, e.g., 1.5, 1.6, 1.7.

[0190] 1.8, etc.) the level of activity in an untreated cell.

[0191] The term “maintain,” or “preserve,” or “maintenance,” or “no change,” or “no substantial change,” or “no substantial decrease” refers generally to a physiological response that is comparable to a response caused by either vehicle, or a control molecule / composition. A comparable response is one that is not significantly different or measurable different from the reference response.

[0192] " Nucleic acid" refers to nucleotides (e.g., deoxyribonucleotides or ribonucleotides) and polymers thereof in either single-, double- or multiple-stranded form, or complements thereof; or nucleosides (e.g., deoxyribonucleosides or ribonucleosides). In embodiments, “nucleic acid” does not include nucleosides. The terms “polynucleotide,” “oligonucleotide,” “oligo” or the like refer, in the usual and customary sense, to a linear sequence of nucleotides. The term “nucleoside” refers, in the usual and customary sense, to a glycosylamine including a nucleobase and a five-carbon sugar (ribose or deoxyribose). Non limiting examples, of nucleosides include, cytidine, uridine, adenosine, guanosine, thymidine and inosine. The term “nucleotide” refers, in the usual and customary sense, to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified versions thereof. Examples of polynucleotides contemplated herein include single and double stranded DNA, single and double stranded RNA, and hybrid molecules having mixtures of single and double stranded DNA and RNA. Examples of nucleic acid, e.g. polynucleotides contemplated herein include any types of RNA, e.g. mRNA, siRNA, miRNA, and guide RNA and any types of DNA, genomic DNA, plasmid DNA, and mini circle DNA, and any fragments thereof. The term “duplex” in the context of polynucleotides refers, in the usual and customary sense, to double strandedness. Nucleic acids can be linear or branched. For example, nucleic acids can be a linear chain of nucleotides or the nucleic acids can be branched, e.g., such that the nucleic acids comprise one or more arms or branches of nucleotides. Optionally, the branched nucleic acids are repetitively branched to form higher ordered structures such as dendrimers and the like.

[0193] Nucleic acids, including e.g., nucleic acids with a phosphothioate backbone, can include one or more reactive moieties. As used herein, the term reactive moiety includes any group capable of reacting with another molecule, e.g., a nucleic acid or polypeptide through covalent, non-covalent or other interactions. By way of example, the nucleic acid can include an amino acid reactive moiety that062460-505001WG reacts with an amio acid on a protein or polypeptide through a covalent, non-covalent or other interaction.

[0194] The terms also encompass nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphodiester derivatives including, e.g., phosphoramidate, phosphorodiamidate, phosphorothioate (also known as phosphothioate having double bonded sulfur replacing oxygen in the phosphate), phosphorodi thioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite linkages (see Eckstein, OLIGONUCLEOTIDES AND ANALOGUES: A PRACTICAL APPROACH, Oxford University Press) as well as modifications to the nucleotide bases such as in 5-methyl cytidine or pseudouridine.; and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, modified sugars, and nonribose backbones (e.g. phosphorodiamidate morpholino oligos or locked nucleic acids (LNA) as known in the art), including those described in U. S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, CARBOHYDRATE MODIFICATIONS IN ANTISENSE RESEARCH, Sanghui & Cook, eds. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. In embodiments, the intemucleotide linkages in DNA are phosphodiester, phosphodiester derivatives, or a combination of both.

[0195] Nucleic acids can include nonspecific sequences. As used herein, the term "nonspecific sequence" refers to a nucleic acid sequence that contains a series of residues that are not designed to be complementary to or are only partially complementary to any other nucleic acid sequence. By way of example, a nonspecific nucleic acid sequence is a sequence of nucleic acid residues that does not function as an inhibitory nucleic acid when contacted with a cell or organism.

[0196] A polynucleotide is typically composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); and thymine (T) (uracil (U) for thymine (T) when the polynucleotide is RNA). Thus, the term “polynucleotide sequence” is the alphabetical representation062460-505001WG of a polynucleotide molecule; alternatively, the term may be applied to the polynucleotide molecule itself. This alphabetical representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching. Polynucleotides may optionally include one or more non-standard nucleotide(s), nucleotide analog(s) and / or modified nucleotides.

[0197] The term “complement,” as used herein, refers to a nucleotide (e g., RNA or DNA) or a sequence of nucleotides capable of base pairing with a complementary nucleotide or sequence of nucleotides. As described herein and commonly known in the art the complementary (matching) nucleotide of adenosine is thymidine and the complementary (matching) nucleotide of guanosine is cytosine. Thus, a complement may include a sequence of nucleotides that base pair with corresponding complementary nucleotides of a second nucleic acid sequence. The nucleotides of a complement may partially or completely match the nucleotides of the second nucleic acid sequence. Where the nucleotides of the complement completely match each nucleotide of the second nucleic acid sequence, the complement forms base pairs with each nucleotide of the second nucleic acid sequence. Where the nucleotides of the complement partially match the nucleotides of the second nucleic acid sequence only some of the nucleotides of the complement form base pairs with nucleotides of the second nucleic acid sequence. Examples of complementary sequences include coding and a non-coding sequences, wherein the non-coding sequence contains complementary nucleotides to the coding sequence and thus forms the complement of the coding sequence. A further example of complementary sequences are sense and antisense sequences, wherein the sense sequence contains complementary nucleotides to the antisense sequence and thus forms the complement of the antisense sequence.

[0198] As described herein the complementarity of sequences may be partial, in which only some of the nucleic acids match according to base pairing, or complete, where all the nucleic acids match according to base pairing. Thus, two sequences that are complementary to each other, may have a specified percentage of nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region).

[0199] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y-carboxy glutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group,062460-505001WG and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. The terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.

[0200] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

[0201] The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may in embodiments be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. A "fusion protein" refers to a chimeric protein encoding two or more separate protein sequences that are recombinantly expressed as a single moiety.

[0202] An amino acid or nucleotide base "position" is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5'-end). Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N-terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.

[0203] The terms "numbered with reference to" or "corresponding to," when used in the context of the numbering of a given amino acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is062460-505001WG compared to the reference sequence. An amino acid residue in a protein "corresponds" to a given residue when it occupies the same essential structural position within the protein as the given residue. One skilled in the art will immediately recognize the identity and location of residues corresponding to a specific position in a protein in other proteins with different numbering systems. For example, by performing a simple sequence alignment with a protein the identity and location of residues corresponding to specific positions of the protein are identified in other protein sequences aligning to the protein. For example, a selected residue in a selected protein corresponds to glutamic acid at position 138 when the selected residue occupies the same essential spatial or other structural relationship as a glutamic acid at position 138. In some embodiments, where a selected protein is aligned for maximum homology with a protein, the position in the aligned selected protein aligning with glutamic acid 138 is the to correspond to glutamic acid 138. Instead of a primary sequence alignment, a three dimensional structural alignment can also be used, e.g., where the structure of the selected protein is aligned for maximum correspondence with the glutamic acid at position 138, and the overall structures compared. In this case, an amino acid that occupies the same essential position as glutamic acid 138 in the structural model is the to correspond to the glutamic acid 138 residue.

[0204] " Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, "conservatively modified variants" refers to those nucleic acids that encode identical or essentially identical amino acid sequences. Because of the degeneracy of the genetic code, a number of nucleic acid sequences will encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

[0205] As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are062460-505001WG well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the disclosure.

[0206] The following eight groups each contain amino acids that are conservative substitutions for one another:

[0207] 1) Alanine (A), Glycine (G);

[0208] 2) Aspartic acid (D), Glutamic acid (E);

[0209] 3) Asparagine (N), Glutamine (Q);

[0210] 4) Arginine (R), Lysine (K);

[0211] 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);

[0212] 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);

[0213] 7) Serine (S), Threonine (T); and

[0214] 8) Cysteine (C), Methionine (M)

[0215] The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site at the World Wide Web (www) at ncbi.nlm.nih.gov / BLAST or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and / or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

[0216] " Percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the062460-505001WG window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Percent identity may also be determined, for example, by comparing sequence information using the advanced BLAST computer program, including version 2.2.9, available from the National Institutes of Health. The BLAST program is based on the alignment method of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990) and as discussed in Altschul, et al., J. Mol. Biol. 215:403-410 (1990); Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993); and Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997). Briefly, the BLAST program defines identity as the number of identical aligned symbols (generally nucleotides or amino acids), divided by the total number of symbols in the shorter of the two sequences. The program may be used to determine percent identity over the entire length of the proteins being compared. Default parameters are provided to optimize searches with short query sequences in, for example, with the blastp program. The program also allows use of an SEG filter to mask-off segments of the query sequences as determined by the SEG program of Wootton and Federhen, Computers and Chemistry 17:149-163 (1993). Ranges of desired degrees of sequence identity are approximately 80% to 100% and integer values therebetween. Typically, the percent identities between a disclosed sequence and a claimed sequence are at least 80%, at least 85%, at least 90%, at least 95%, or at least 98%.

[0217] A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of, e.g., a full length sequence or from 20 to 600, about 50 to about 200, or about 100 to about 150 amino acids or nucleotides in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1970)74t / v. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat ’I. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)).

[0218] An example of an algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nuc. Acids Res. 25:3389-3402, and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National062460-505001WG Center for Biotechnology Information (see, the World Wide Web (www) at ncbi.nlm.nih.gov). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

[0219] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

[0220] An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under062460-505001WG stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.

[0221] For preparation of monoclonal or polyclonal antibodies, any technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy (1985)). " Monoclonal" antibodies (mAb) refer to antibodies derived from a single clone. Techniques for the production of single chain antibodies (U. S. Pat. No. 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)).

[0222] The epitope of a antibody is the region of its antigen to which the antibody binds. Two antibodies bind to the same or overlapping epitope if each competitively inhibits (blocks) binding of the other to the antigen. That is, a 1x, 5x, 10x, 20x or 100x excess of one antibody inhibits binding of the other by at least 30% but preferably 50%, 75%, 90% or even 99% as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 50:1495, 1990). Alternatively, two antibodies have the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

[0223] By “detuned” is a variant of an antibody or domain thereof (e.g., VH, VH, VHH, or CDR) that has reduced affinity for its target due to one or more mutations in its amino acid sequence. Illustrative detuned anti-HSA VHH domains having reduced capacity for binding HSA due to one or more mutations relative to a wild type anti-HSA VHH, are shown in Table 1 and comprises a sequence at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49. Specific useful mutations are found in Table 6. In some cases, the wild type anti-HSA VHH has the sequence of SEQ ID NO: 1.

[0224] For preparation of suitable antibodies of the invention and for use according to the invention, e.g., recombinant, monoclonal, or polyclonal antibodies, many techniques known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). The062460-505001WG genes encoding the heavy and light chains of an antibody of interest can be cloned from a cell, e.g., the genes encoding a monoclonal antibody can be cloned from a hybridoma and used to produce a recombinant monoclonal antibody. Gene libraries encoding heavy and light chains of monoclonal antibodies can also be made from hybridoma or plasma cells. Random combinations of the heavy and light chain gene products generate a large pool of antibodies with different antigenic specificity (see, e.g., Kuby, Immunology (3rd ed. 1997)). Techniques for the production of single chain antibodies or recombinant antibodies (U. S. Patent 4,946,778, U. S. Patent No. 4,816,567) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized or human antibodies (see, e.g., U. S. Patent Nos.

[0225] 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, Marks et al., Bio / Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); and Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995)). Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)). Antibodies can also be made bispecific, i.e., able to recognize two different antigens (see, e.g., WO 93 / 08829, Traunecker et al., EMBO J. 10:3655-3659 (1991); and Suresh et al., Methods in Enzymology 121:210 (1986)). Antibodies can also be heteroconjugates, e.g., two covalently joined antibodies, or immunotoxins (see, e.g., U. S. Patent No. 4,676,980, WO 91 / 00360; WO 92 / 200373; and EP 03089).

[0226] Methods for humanizing or primatizing non-human antibodies are well known in the art (e.g., U. S. Patent Nos. 4,816,567; 5,530,101; 5,859,205; 5,585,089; 5,693,761; 5,693,762; 5,777,085; 6,180,370; 6,210,671; and 6,329,511; WO 87 / 02671; EP Patent Application 0173494; Jones et al. (1986) Nature 321:522; and Verhoyen et al. (1988) Science 239:1534). Humanized antibodies are further described in, e g., Winter and Milstein (1991) Nature 349:293. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers (see, e.g., Morrison et al., PNAS USA, 81:6851-6855 (1984), Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Morrison and Oi, Adv. Immunol., 44:65-92 (1988), Verhoeyen et al., Science 239:1534-1536 (1988) and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992), Padlan, Molec. Immun, 28:489-498 (1991); Padlan, Molec. Immun., 31(3): 169-217 (1994)), by substituting rodent CDRs or CDR sequences for the062460-505001WG corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U. S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. For example, polynucleotides comprising a first sequence coding for humanized immunoglobulin framework regions and a second sequence set coding for the desired immunoglobulin complementarity determining regions can be produced synthetically or by combining appropriate cDNA and genomic DNA segments. Human constant region DNA sequences can be isolated in accordance with well known procedures from a variety of human cells.

[0227] The phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein, often in a heterogeneous population of proteins and other biologies. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies can be selected to obtain only a subset of antibodies that are specifically immunoreactive with the selected antigen and not with other proteins. This selection may be achieved by subtracting out antibodies that crossreact with other molecules. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual (1998) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).

[0228] A "ligand" refers to an agent, e g., a polypeptide or other molecule, capable of binding to a receptor or antibody, antibody variant, antibody region or fragment thereof.

[0229] Techniques for conjugating therapeutic agents to antibodies are well known (see, e.g., Arnon et al., " Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds ), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., “Antibodies For Drug Delivery”in Controlled Drug Delivery (2ndEd.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, " Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review" in Monoclonal Antibodies ‘84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorpe et al., " The Preparation And Cytotoxic Properties Of062460-505001WG Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982)). As used herein, the term “antibodydrug conjugate” or “ADC” refers to a therapeutic agent conjugated or otherwise covalently bound to to an antibody.

[0230] For specific proteins described herein, the named protein includes any of the protein’s naturally occurring forms, variants or homologs that maintain the protein transcription factor activity (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the native protein). In some embodiments, variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring form. In other embodiments, the protein is the protein as identified by its NCBI sequence reference. In other embodiments, the protein is the protein as identified by its NCBI sequence reference, homolog or functional fragment thereof.

[0231] " Contacting" is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. antibodies and antigens) to become sufficiently proximal to react, interact, or physically touch. It should be appreciated; however, that the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture.

[0232] The term "contacting" may include allowing two species to react, interact, or physically touch, wherein the two species may be, for example, a pharmaceutical composition as provided herein and a cell. In embodiments contacting includes, for example, allowing a pharmaceutical composition as described herein to interact with a cell (e.g. a T cell).

[0233] A "cell" as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaryotic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include, but are not limited to, yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells.

[0234] The term "isolated", when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It can be, for example, in a homogeneous state and may be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as062460-505001WG polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified.

[0235] As defined herein, the term "inhibition", "inhibit", "inhibiting" and the like in reference to cell proliferation (e.g., autoimmune effector cell proliferation) means negatively affecting (e.g., decreasing proliferation) or killing the cell. In some embodiments, inhibition refers to reduction of a disease or symptoms of disease (e.g., an autoimmune disease or inflammatory disease or a graft-versus-host disease (GVHD)). Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein.

[0236] The term “modulate”, “modulates”, “modulating”, “modulation” and the like relates to a change in a process, e.g., in an amount of the process and the rate of a process. The change may be an increase or may be a decrease.

[0237] The term “activate”, “increase”, “enhance”, “potentiate”, “amplify” and the like relates to an increase in a process, e.g., in an amount of the process and the rate of a process.

[0238] As defined herein, the term “activate”, “increase”, “enhance”, “potentiate”, “amplify” and the like means positively affecting an activity of a cell. Thus, activation includes, at least in part, partially or totally enhancing stimulation, increasing, potentiating, or accelerating activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein. Similarly, an "agonist" is a compound or protein that activates a receptor or another protein, e.g, by binding, increasing, potentiating, accelerating, activating, sensitizing, or up-regulating activity (e.g., a receptor activity or a protein activity).

[0239] Thus, the terms “activator,” “enhancer” or “agonist” or “upregulator” or “potentiator” or “stimulator” interchangeably refer to a substance capable of detectably increasing the expression or activity of a given gene or protein (e.g. CD2 protein or intracellular proteins bound to CD2). The agonist can increase protein expression or activity 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300% or more in comparison to a control in the absence of the agonist. In certain instances, CD2 expression or activity, or activity of CD2-associated intracellular proteins, is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist.

[0240] The term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques062460-505001WG for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).

[0241] “Biological sample” or “sample” refer to materials obtained from or derived from a subject or patient. A biological sample includes sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histological purposes. Such samples include bodily fluids such as blood and blood fractions or products (e.g., serum, plasma, platelets, red blood cells, and the like), sputum, tissue, cultured cells (e.g., primary cultures, explants, and transformed cells) stool, urine, synovial fluidjoint tissue, synovial tissue, synoviocytes, fibroblast-like synoviocytes, macrophage-like synoviocytes, immune cells, hematopoietic cells, fibroblasts, macrophages, T cells, etc. A biological sample is typically obtained from a eukaryotic organism, such as a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

[0242] A “control” or “standard control” refers to a sample, measurement, or value that serves as a reference, usually a known reference, for comparison to a test sample, measurement, or value. For example, a test sample can be taken from a patient suspected of having a given disease and compared to a known normal (non-diseased) individual (e.g. a standard control subject). A standard control can also represent an average measurement or value gathered from a population of similar individuals (e.g. standard control subjects) that do not have a given disease (i.e. standard control population), e g., healthy individuals with a similar medical background, same age, weight, etc. A standard control value can also be obtained from the same individual, e.g. from an earlier-obtained sample from the patient prior to disease onset. For example, a control can be devised to compare therapeutic benefit based on pharmacological data (e.g., half-life) or therapeutic measures (e.g., comparison of side effects). Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples will not be considered as significant. One of skill will recognize that standard controls can be designed for assessment of any number of parameters (e.g. RNA levels, protein levels, specific cell types, specific bodily fluids, specific tissues, etc).

[0243] One of skill in the art will understand which standard controls are most appropriate in a given situation and be able to analyze data based on comparisons to standard control values. Standard controls are also valuable for determining the significance (e.g. statistical significance) of data. For example, if values for a given parameter are widely variant in standard controls, variation in test samples will not be considered as significant.

[0244] “Patient” or “subject in need thereof’ refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a composition or pharmaceutical062460-505001WG composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.

[0245] The terms “disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. The disease may be an autoimmune disease or inflammatory disease or a graft-versus-host disease (GVHD). In embodiments, the autoimmune disease or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

[0246] The term “associated” or “associated with” in the context of a substance or substance activity or function associated with a disease (e.g. a protein associated disease (e.g., inflammatory disease or autoimmune disease)) means that the disease is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function. As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease.

[0247] The term “signaling pathway” as used herein refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propagated to other signaling pathway components.

[0248] The term "aberrant" as used herein refers to different from normal. When used to describe enzymatic activity, aberrant refers to activity that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non-disease-associated amount (e.g. by using a method as described herein), results in reduction of the disease or one or more disease symptoms.

[0249] A "therapeutic agent" as referred to herein, is a composition useful in treating or preventing a disease such an autoimmune disease or inflammatory disease or suppressing graft-versus-host disease (GVHD).

[0250] As used herein, “treating” or “treatment of’ a condition, disease or disorder or symptoms associated with a condition, disease or disorder refers to an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not062460-505001WG limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of condition, disorder or disease, stabilization of the state of condition, disorder or disease, prevention of development of condition, disorder or disease, prevention of spread of condition, disorder or disease, delay or slowing of condition, disorder or disease progression, delay or slowing of condition, disorder or disease onset, amelioration or palliation of the condition, disorder or disease state, and remission, whether partial or total. “Treating” can also mean prolonging survival of a subject beyond that expected in the absence of treatment. “Treating” can also mean inhibiting the progression of the condition, disorder or disease, slowing the progression of the condition, disorder or disease temporarily, although in some instances, it involves halting the progression of the condition, disorder or disease permanently. As used herein the terms treatment, treat, or treating refers to a method of reducing the effects of one or more symptoms of a disease or condition characterized by expression of the protease or symptom of the disease or condition characterized by expression of the protease. Thus in the disclosed method, treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease, condition, or symptom of the disease or condition. For example, a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject as compared to a control. Thus the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition. Further, as used herein, references to decreasing, reducing, or inhibiting include a change of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater as compared to a control level and such terms can include but do not necessarily include complete elimination.

[0251] The terms “prevent,” and similar words such as “prevented,” “preventing” etc., indicate an approach for preventing, inhibiting, or reducing the likelihood of a symptom of disease. It also refers to delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease. As used herein, “prevention” and similar words also includes reducing the intensity, effect, symptoms and / or burden of disease prior to onset or recurrence.

[0252] The terms “dose” and “dosage” are used interchangeably herein. A dose refers to the amount of active ingredient given to an individual at each administration. The dose will vary depending on a number of factors, including the range of normal doses for a given therapy, frequency of administration; size and tolerance of the individual; severity of the condition; risk of side effects; and the route of administration. One of skill will recognize that the dose can be modified depending on the above factors or based on therapeutic progress. The term “dosage form” refers to the particular062460-505001WG format of the pharmaceutical or pharmaceutical composition, and depends on the route of administration. For example, a dosage form can be in a liquid form for nebulization, e.g., for inhalants, in a tablet or liquid, e.g., for oral delivery, or a saline solution, e.g., for injection.

[0253] By “therapeutically effective dose or amount” as used herein is meant a dose that produces effects for which it is administered (e g. treating or preventing a disease). The exact dose and formulation will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro, Editor (2003), and Pickar, Dosage Calculations (1999)). For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a standard control. A therapeutically effective dose or amount may ameliorate one or more symptoms of a disease. A therapeutically effective dose or amount may prevent or delay the onset of a disease or one or more symptoms of a disease when the effect for which it is being administered is to treat a person who is at risk of developing the disease.

[0254] As used herein, the term "administering" means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. By "coadminister" it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies, for example an immunosuppressant or immunotherapy. The compounds of the invention can be administered alone or can be coadministered to the patient. Coadministration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation). The compositions of the present invention can be delivered by062460-505001WG transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

[0255] The compositions of the present invention may additionally include components to provide sustained release and / or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U. S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present invention can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res.

[0256] 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol.

[0257] 49:669-674, 1997). In embodiments, the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo. (See, e.g., Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576-1587, 1989). The compositions of the present invention can also be delivered as nanoparticles.

[0258] As used herein, the term “pharmaceutically acceptable” is used synonymously with “physiologically acceptable” and “pharmacologically acceptable”. A pharmaceutical composition will generally comprise agents for buffering and preservation in storage, and can include buffers and carriers for appropriate delivery, depending on the route of administration.

[0259] " Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be062460-505001WG sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and / or aromatic substances and the like that do not deleteriously react with the compounds of the invention. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.

[0260] The term "pharmaceutically acceptable salt" refers to salts derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

[0261] The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0262] The pharmaceutical preparation is optionally in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. The unit dosage form can be of a frozen dispersion.

[0263] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in the application including, without limitation, patents, patent applications, articles, books, manuals, and treatises are hereby expressly incorporated by reference in their entirety for any purpose.

[0264] The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.

[0265] While various embodiments and aspects of the present invention are shown and described herein, it will be obvious to those skilled in the art that such embodiments and aspects are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention.062460-505001WG Note, the specific features (e.g., antibody regions) described herein are illustrative of all covered serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0266] Any aspect or embodiment described herein can be combined with any other aspect or embodiment as disclosed herein.

[0267] EXAMPLES EXAMPLE 1:

[0268] To explore whether PDlxCD2 trispecific antibodies with a different format were also PD-1 agonists, single chain VHH molecules (scVHH) were generated in which the PD1 and CD2 specific VHH domains were linked in a single amino acid chain. As the in vivo pharmacology of such molecules may suffer from a short half-life, a third VHH specific for human serum albumin (HSA) was included to increase retention in circulation (See, van Faassen H, et. al.., “Serum albumin-binding VHHs with variable pH sensitivities enable tailored half-life extension of biologies. FASEB J. 2020 Jun;34(6):8155-8171.). The three VHHs were linked in different orientations with different linkers to form a panel of forty-eight (48) candidates, and these sequences were expressed as either single chains or as Fc-fused homodimers (FIG. IB and Table 4)

[0269] Table 4 Illustrative Serially Linked VHHs062460-505001WG

[0270]

[0271] 062460-505001WG

[0272]

[0273] 062460-505001WG

[0274]

[0275] 062460-505001WG

[0276]

[0277] 062460-505001WG

[0278]

[0279] 062460-505001WG

[0280]

[0281] 062460-505001WG

[0282]

[0283] 062460-505001WG

[0284]

[0285] 062460-505001WG

[0286]

[0287] 062460-505001WG

[0288]

[0289] 062460-505001WG

[0290]

[0291] 062460-505001WG

[0292]

[0293] 062460-505001WG

[0294]

[0295] 062460-505001WG

[0296]

[0297] 062460-505001WG

[0298]

[0299] 062460-505001WG

[0300]

[0301] 062460-505001WG

[0302]

[0303] 062460-505001WG

[0304]

[0305] 062460-505001WG

[0306]

[0307] 062460-505001WG

[0308]

[0309] 062460-505001WG

[0310]

[0311] 062460-505001WG

[0312]

[0313] 062460-505001WG

[0314]

[0315] 062460-505001WG

[0316]

[0317] 062460-505001WG

[0318]

[0319] 062460-505001WG

[0320]

[0321] 062460-505001WG

[0322]

[0323] In Table 4, the named multivalent antibodies including the letter “t” after the number are truncated versions of the multivalent antibodies. These truncated multivalent antibodies lack the C- terminal alanine triplet (AAA) which is present in the multivalent antibodies lacking the letter “f In various embodiments, a multivalent antibody of the present disclosure may include the C-terminal alanine triplet or may lack the C-terminal alanine triplet. The C-terminal alanine triplet may help prevent Anti Drug Antibody (ADA) response (pre-existing ADA), which may affect the function and PK of the multivalent antibodies when used. The AAA may occlude and / or mask an epitope in VHHs that is known to be immunogenic. The terminal AAA may be omitted from a sequence if the multivalent comprise a C-terminal constant region, e.g.,. See FIG. IB. FIG. IB shows that a serial linked VHH has an AAA or a constant region (exemplified there as His-TEV-Fc); however, a serial linked VHH can have both an AAA and a constant region. Any of the herein disclosed multivalent antibodies may further comprise a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 57 and a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 58 or 59.

[0324] The majority of the trispecific antibodies exhibited potentPD-1 agonism in a Jurkat-PDl assay (FIG. 2). The linear orientation of the three VHH domains did not have a dramatic effect on potency.

[0325] This example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.062460-505001WG EXAMPLE 2:

[0326] Because the scVHH molecules contained an HSA binding domain, their association with HSA could be predicted to restrict access to the synapse and reduce potency. Thus, T cell suppression by scVHH and Fc-fused mvAbs were evaluated in the MLR with either bovine or human serum supplementation.

[0327] In an MLR performed in AIM-V media with 3% human serum (HS), two scVHH test articles (scVhh-25, scVhh-30) were slightly less potent than two different PD1 x CD2 knob-in-hole (KiH) Fc-fusion test articles (PDIVhhJ x CD2VhhDD, PDIVhhJ x CD2VhhAP), and none of these constructs promoted PD-1 agonism to the same degree as endogenous PD-1 ligand expression on the moDC (no a-PDLl / 2) (FIG.3A). In contrast, an MLR performed in RPMI media with 10% bovine serum (FBS) revealed a marked increase in potency of the same scVHH test articles while the Fc-fused mvAbs exhibited the same degree of partial T cell suppression (FIG. 3B). The increase in scVHH activity was observed in both EC-50 (approximately lOOx reduction) and Emax, where suppression matched that observed when PD-1 ligands expressed on the moDC were not blocked by anti-PD-Ll + anti-PD-L2 antibodies (dotted line).

[0328] To explore the impact of HSA binding in HS-containing culture conditions, scVHH constructs were generated where the HSA- or the PD-1 -specific VHH was replaced with a VHH specific for Campylobacter jejuni flagella (CjeF), which has no binding activity in the experimental system (See, Riazi A, “Pentavalent single-domain antibodies reduce Campylobacter jejuni motility and colonization in chickens.” PLoS One. 2013 Dec 31;8(12):e83928). In an MLR cultured in AIM-V media with 3% HS, the absence of the HSA binding VHH (scVhh-55, scVhh-56) again increased potency ~100x compared to the HSA-binding constructs (scVhh-49, scVhh-50) (FIG. 4). As expected, replacement of the PD-1 VHH with the CjeF VHH (scVhh-53, scVhh-54) completely abrogated activity. Thus, the scVHH format enabled complete recapitulation of PD-1 agonism by high levels PD-1 ligands on antigen presenting cells. The scVHH constructs had sequences shown in Table 5.

[0329] Table 5:

[0330]

[0331] 062460-505001WG

[0332]

[0333] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0334] EXAMPLE 3:062460-505001WG Since CD2 is broadly expressed on all T cells, it is preferable that the antibody specifically binds to CD2 and PD-1 co-expressing cells to enable target-specific delivery. Binding to CD2 on PD-1 cells may result in a high degree of undesirable target-mediated drug deposition. To test PD-1 dependent CD2 engagement, PD1 x CD2 in KiH and scVHH formats and their corresponding CD2-only control test articles were evaluated for CD2 receptor occupancy (RO) in PD-1 knockout (KO) and PD-1 -expressing Jurkat T cells, as well as human tonsil cells containing both PD-1+and PD-1 T cell populations. After staining cells with titrations of the test articles, receptor occupancy was determined by staining with a fluorescently labeled anti-CD2 antibody that binds the same region as the CD2 VHH, of the present disclosure, followed by flow cytometry. A PD1 x CD2 KiH and a PD1. CD2. HSA scVHH demonstrated a dose-dependent increase in CD2 RO, whereas the CD2-only control antibodies failed to bind CD2 on PD-1 -expressing Jurkat cells (FIG. 5, top left). In PD-1 KO Jurkat cells, neither the mvAbs nor the CD2-only control antibodies bound to CD2 (FIG.5, top right). Consistently, the mvAbs increased CD2 RO in PD-1+human primary tonsil T cells, while only minimal CD2 RO was observed with CD2-only control antibodies and in PD-1 T cells (FIG. 5, bottom left and bottom right). The data supports that CD2 engagement is dependent on PD-1 binding on T cells, demonstrating target-specific delivery of the multivalent antibody to T cell subsets that coexpress both CD2 and PD-1.

[0335] As noted above, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second targetspecific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0336] EXAMPLE 4:

[0337] Inhibition of inflammatory cytokine response by a PD1. CD2. HSA scVHH compared to the benchmark PD-1 agonist antibody, rosnilimab (identified in the figure as PDlIgGl A), in PBMC from a rheumatoid arthritis patient was assessed. PBMC were incubated with SEB (4 ng / mL) and the indicated concentrations of scVhh-25 or rosnilimab for 4 days at 37°C. Supernatants were analyzed using the Human Cytokine / Chemokine 71-Plex Discovery Assay® Array (Eve Technologies, HD71). The scVhh-25 embodiment suppressed the production of multiple pro-inflammatory cytokines and chemokines, whereas rosnilimab exhibited inhibitory activity in only a few cytokines primarily produced by T cells, such as IFN-y, IL-23, and CXCL13. Interestingly, rosnilimab induced pro-inflammatory cytokines, including TNF-a, IL-6, IL-10, and G-CSF, possibly through the activation of FcyR signaling (FIG. 6). The data demonstrated the immunosuppressive activity of the062460-505001WG PD1. CD2. HSA scVhh-25 and suggests that rosnilimab induces pro-inflammatory cytokine responses, which may potentially undermine its pharmacological effects.

[0338] This example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0339] EXAMPLE 5:

[0340] The high potency of the scVHH format results from greater PD-1 phosphorylation and SHP2-mediated suppression was confirmed. To verify this, a PD1 x CD2 KiH and a PD1. CD2. HSA scVHH were tested with the tyrosine mutant Jurkat-PDl cell lines The PD-1 agonists were found to function in a Jurkat-PDl + Raji assay stimulated with CytoStim (Miltenyi 130-092-172), thus, CytoStim (1:5000 dilution) was used as the agonist in this experiment.

[0341] The scVHH was more potent than the KiH at suppressing the IL-2 production and CD69 upregulation (compare FIG. 7A and FIG. 7B and FIG. 7C and FIG. 7D). While the modest suppression observed with the KiH and the scVHH were similar with the Y248F and the Y223F Y248F (double) mutants, agonism of the WT and Y223F PD-1 versions was more pronounced with the scVHH than the KiH for both IL-2 and CD69 suppression. Thus, the increased potency of the scVHH format is likely due to more complete or more efficient PD-1 phosphorylation, perhaps due to better PD-1 recruitment to its optimal location within the synapse.

[0342] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0343] EXAMPLE 6:

[0344] Suppression of the Jurkat-PDl response by the scVHH PD-1 agonists was reduced in the presence of 3% HS vs. 10% FBS. An assay (Jurkat-PDlmidcells + Raji + CytoStim) screened a panel of PD1. CD2. VHH scVHH constructs with mutations in the HSA-binding VHH predicted to reduce affinity based on the solved VHH: HSA structure (PDB ID 8Z8V), with the aim of finding variants with fully restored potency in the presence of HS.

[0345] Mutations to the HSA-binding VHH were identified by predicting changes in binding affinity between the HSA-binding VHH and HSA, using PDB ID 8Z8V in MOE (Chemical Computing Group). Residues S31, G33, G53, S101, S103, and S105 on the HSA-binding VHH exhibited062460-505001WG hydrogen bonds with HSA. These hydrogen bonding residues and all residues in CDR3 (Kabat definition) were individually replaced with 13 amino acids (A, E, F, G, H, I, K, L, Q, R, S, T, V), and the change in binding affinity for each mutant was calculated. Nineteen mutants of the HSA-binding VHH were selected such that the predicted changes in binding affinities spanned the range observed in the virtual mutagenesis campaign (Table 6).

[0346] Table 6:

[0347]

[0348] Mutants of the HSA-binding VHH were expressed and purified in the PD1. CD2. HSA scVHH format and binding affinities against biotinylated HSA were measured on an Octet RH16 using SA biosensors (Sartorius). HSA-binding VHH mutants exhibited KD values against HSA that ranged between 14-527 nM (parental KD: 15 nM), and exhibited strong correlation with the changes in binding affinity predicted in silico (FIG. 8).

[0349] The panel of “HS A-detuned” scVHHs (SEQ ID NO: 65 to SEQ ID NO: 217, which included062460-505001WG a detuned HSA binding domain of one of SEQ ID NO: 2 to SEQ ID NO: 49) demonstrated a distribution of potency in the Jurkat-PDl assay (FIG.9A). The lower affinity variants and the variants with undetectable affinity were more potent than the higher affinity variants and the parental HSA VHH, with a bifurcation in potency observed at approximately 100 nM KD (FIG. 9B). Importantly, several low affinity variants exhibited the same potency as non-binding variants. These data demonstrate that a desired HSA affinity for a therapeutic PD1. CD2. HSA scVHH is between 100 and 1000 nM.

[0350] As mentioned above, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second targetspecific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0351] EXAMPLE 7:

[0352] An illustrative scVHH with a detuned anti-HSA antibody region (comprising anti-PD-1 and anti-CD2 VHH domains) was compared to a PD-1 IgG monoclonal antibody (rosnilimab). As shown in FIG. 10A, the illustrative scVHH had more potent agonism in suppressing IFN- y in whole PBMCs than rosnilimab. The PBMCs contain CD 16+ APCs and NK cells. FIG. 10B shows data from four illustrative scVHH with a detuned anti-HSA antibody region which had more potent agonism in suppressing IFN- y in whole PBMCs than rosnilimab. In this data, PBMC were exposed to CytoStim, for two days. PD-L1 and PD-L2 blocking Abs were added to all conditions except where noted (dotted line).

[0353] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0354] EXAMPLE 8:

[0355] To test if the PD1. CD2. HSA scVHH variants with low HSA affinity “HSA-detuned” also exhibited improved potency in primary cell assays, select variants were tested in AIM-V media + 3% human serum (HS) in a T cell + moDC MLR (FIG. 11 A) and in a whole PMBC assay stimulated with the CEFX antigenic peptide pool (JPT) (FIG. 11B). The activities of the test articles correlated with the 1C50 values obtained from the Jurkat-PDl response.

[0356] For the CEFX response, whole PBMC (300,000) were stimulated with 0.4 pg / mL CEFX peptides for 4 days, after which IFN-y in the supernatant was quantified. Test articles were titrated in the presence of anti-PD-Ll, PD-L2 antibodies. The response to 2 test articles with low and062460-505001WG intermediate HSA affinities is shown in FIG. 11B, demonstrating high potency of the low affinity variant that surpassed activity of endogenous PD-1 ligands (dotted line).

[0357] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0358] EXAMPLE 9:

[0359] PD1 x CD2 multivalent antibodies of the present disclosure were tested for their ability to suppress a Type 1 diabetes (T1D) patient’s T cell response to pancreatic islet antigens. In this experiment, a T1D patient’s PBMCs were stimulated with islet antigen peptide pool along with the test articles (Fc x Fc control, PDl. CD2. CjeF scVhh-56, or PDIVhhJ x CD2VhhDD).

[0360] The stimulated PBMCs were then expanded for 14 days. Finally, the cells were restimulated with DMSO or the islet antigen peptides. The number of expanded peptide-specific CD4 T cells were quantified by flow cytometry (CD69+CD154+). Flow cytometry plots are shown in FIG. 12A, with the data characterized in the graph of FIG. 12B. As shown, the PD1 x CD2 multivalent antibodies of the present disclosure reduced expansion of the pancreatic islet antigens stimulated PBMC. These data show that the PD1 x CD2 multivalent antibodies of the present disclosure suppress a Type 1 diabetes patient’s T cell response to pancreatic islet antigens and, thus, can be used as a therapeutic for preventing or reducing islet cell loss resulting from Type 1 diabetes.

[0361] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0362] EXAMPLE 10:

[0363] To determine what immunomodulatory factors are altered in the presence of PD-lxCD2 multivalent antibodies of the present disclosure and could serve as potential biomarkers in a clinical setting, PBMC from a Rheumatoid arthritis (RA) patient were treated with PDlxCD2 multivalent antibodies of the present disclosure and RNA generated to screen in a Nanostring® autoimmune panel of 770 selected genes.

[0364] PBMC (300,000 / well in RPMi + 10% FBS) obtained from a rheumatoid arthritis patient were incubated for 24 hours with a T cell activating reagent (CytostimTM; Miltenyi Biotech, 1: 5000), anti-PD-L1 / PD-L2 blocking antibody (5 nM), and test articles (5nM): C6713 (PD-lxCD2-Fc), C7098 (PD-062460-505001WG lxCD2 scVHH), Rosnilimab, or no antibody (control). Each condition was performed in triplicate. The anti-PD-Ll / -L2 antibody was included to eliminate any PDl-related stimulatory effects that could be derived from endogenous signaling via PD-L1 expression on cells in the PBMC culture. In this manner any effects resulting from PD-1 agonism would have been derived from the PD-lxCD2 multivalent antibodies or the other test article.

[0365] After 24 hours, cells from triplicate wells were pooled, and RNA was isolated using RNeasy Mini Kit (Qiagen) and analyzed using Nanostring® nCounter®-Human autoimmune profiling panel (Alexa Biosciences). Two independent software analysis methods (Nanostring nSolver® and Rosalind) yielded similar results.

[0366] Treatment with either PD-lxCD2 multivalent antibody of the present disclosure resulted in decreased expression of genes regulating Thl, Th2, and Thl7 differentiation as well as cytotoxicity. The data also shows that the PD-lxCD2 multivalent antibody of the present disclosure resulted in decreased expression of genes relating to cytokine / chemokine responses. Specifically, the cytokine IL-21 (FIG. 13A) and the chemokine CXCL13 (FIG. 13B) were found to be decreased in the presence of all treatments, to varying levels, compared to control. Both IL-21 and CXCL13 serve as biomarkers for several autoimmune diseases including Type 1 diabetes, rheumatoid arthritis and multiple sclerosis. These data demonstrate that alterations in these factors, at least, following treatment with of PD-lxCD2 multivalent antibodies of the present disclosure are predictive of treatment response..

[0367] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0368] EXAMPLE 11:

[0369] The potencies of two selected scVHH test articles were compared to that of rosnilimab in whole PBMC cultures stimulated with CEFX as described above, except anti-PD-Ll and anti-PD-L2 antibodies were not included in this experiment. Rosnilimab (identified in the figure as PDlIgGlA) exhibited similar potency to the scVHH test articles only with 158-V / V high-affinity FcyRIIIa PBMC donors (FIG. 14A). In contrast, rosnilimab (identified in the figure as PDlIgGlA) was inactive with 158-F / F low-affinity FcyRIIIa PBMC donors (FIG. 14B). These results demonstrate that the PD-1 agonists described in the present disclosure suppress T cell responses in the presence of PD-1 ligands, and that rosnilimab function may be limited to patients with high-affinity Fc-receptors..

[0370] Note, this example is illustrative of serially linked VHH type antibodies of the present062460-505001WG disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

[0371] EXAMPLE 12:

[0372] To explore whether the scVHH format of the present disclosure stimulated PD-1 phosphorylation and PD-1 / SHP2 association to the same extent as endogenous PD-L1 expressed on APCs, and whether the scVHH could further stimulate PD-1 in the presence of APCs expressing high levels of PD-L1, the PD-1 / SHP2 co-immunoprecipitation experiment described above (EXAMPLE 5, FIG. 9) was repeated with the indicated test articles in media containing 3% human serum (HS).

[0373] For this experiment, PD-1 was immunoprecipitated from the Jurkat-1G4-PD1 Raji-A2+pNY co-cultures and analyzed by quantitative tandem mass spectrometry using targeted parallel reaction monitoring (PRM). Immunopurified material was digested with lysyl endopeptidase (LysC - Wako) and Trypsin (Promega). Digested peptides were desalted on XTR 2mg Supel Swift HLB tips (DPX Technologies). Scouting runs using label-free data-independent acquisition (DIA) were used to identify peptides for targeted quantitative analysis. Five SHP2 peptides (ESQSHPGDFVLSVR, INAAEIESR, MVFQENSR, SGMVQTEAQYR, GHEYTNIK) and three PD-1 peptides (LAAFPEDR, VTQLPNGR, DFHMSVVR) were chosen and targeted for HCD fragmentation and high-resolution MS2 scans on a Thermo Orbitrap Eclipse mass spectrometer using mass-to-charge and observed retention times. Data were analyzed in Skyline (v. 25.1.0.237). The sum of the area under the curve for all SHP2 peptides was normalized to values for PD-1. The reported values reflect the amount of recovered co-immunopurified SHP2 relative to the target, PD-1.

[0374] In the presence of Raji-A2 APCs that did not express PD-L1, both scVHH-74 and PDIVhhJ x CD2VhhDD stimulated a high degree of PD-1 / SHP2 association that exceed that obtained with Raji-A2-PDL1 APCs (FIG. 15). Furthermore, both scVHH-74 and PD 1 VhhJ x CD2VhhDD increased PD-1 / SHP2 association in the presence of Raji-A2-PDL1 APCs, with scVHH-74 being more potent than PDIVhhJ x CD2VhhDD (FIG. 15). In contrast, the scVHH isotype control (CjeF. CjeF. HSA) and the PDIVhhJ x Fc monospecific control were inactive. These results demonstrated that the preferred constructs functioned as potent PD-1 agonist with activities that surpassed that obtained with high endogenous PD-L1 expression.

[0375] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.062460-505001WG EXAMPLE 13:

[0376] Additional variants of an HSA-binding VHH were designed and tested for HSA affinity (Table 7). In the Jurkat / Raji assay containing 3% human serum (HS), the potency of PD1. CD2. HSA scVHHs containing these new HSA VHHs again correlated with HSA affinity (FIG. 16A). Select dose response curves are displayed in FIG. 16B. Similar results were obtained with the T cell + moDC MLR in AIM-V media + 3% HS (FIG. 16C).

[0377] Table 7

[0378]

[0379] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.062460-505001WG EXAMPLE 14

[0380] Pharmacokinetic (PK) studies were conducted using mice transgenic for HSA and human FcRn and deficient formouse serum albumin and mouse FcRn. Mice received 3 mg / kg test article via intravenous injection, and blood samples (50-100 pF, retro-orbital collection) were collected at the indicated timepoints. Blood samples were allowed to clot at room temperature in Microvette Serum Gel tubes and then centrifuged at 10,000 RCF to obtain serum. Serum samples were stored at -80°C until analysis. Concentrations of the test article in serum were determined with a validated AlphaLISA assay employing recombinant CD2 and PD-1 fusion proteins (AcroB iosystems). Calibration standards matching each test article and quality control samples were included in each analytical run to ensure accuracy and precision. PK parameters, including Cmax, Tmax and half-life, were calculated using non-linear regression fit curve in Graph Pad Prism vlO.6.1.

[0381] In one experiment, PK of two PD1. CD2. HSA scVHH test articles were compared to a PDl. CD2. CjeF (scVhh-55) control test article that did not bind HSA in genO-hsa / hFcRn mice (GenOway) (FIG. 17A). The results demonstrated that HSA binding markedly increased the half-life of the scVHH test articles, and that an approximately 30-fold reduction in HSA affinity did not markedly reduce half-life (scVhh-57 vs. scVhh-74; Table 8). In a second experiment, the PK of three PD1. CD2. HSA scVHH test articles were determined in Tg32 hALB mice (JAX#037524) (FIG. 17B).

[0382] This study demonstrated that an approximately 2-fold range of HSA affinities in the high-nanomolar range did not markedly alter half-life (Table 8). Thus, PD1 CD2. HSA scVHH candidate therapeutics retain the desirable PK conferred by HSA binding without sacrificing potency of PD-1 agonism in the presence of HSA.

[0383] Table 8.

[0384]

[0385] 1as shown in FIG. 17A

[0386] 2as shown in FIG. 17B

[0387] Note, this example is illustrative of serially linked VHH type antibodies of the present disclosure. Other first target-specific antibody regions (other than PD-1) and a second target-specific antibody regions (other than CD2) will operate similarly to as disclosed here.

Claims

062460-505001WGCLAIMSWhat is claimed is:

1. A bispecific antibody comprising a detuned anti-HSA antibody region and a first target-specific antibody region.

2. The bispecific antibody of claim 1, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are each variable domains on a heavy chain (VHH).

3. The bispecific antibody of any one of claims 1-2, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are serially linked.

4. The bispecific antibody of any one of claims 1-3, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are serially linked via a linker, e.g., of SEQ ID NO: 60 to 64.

5. The bispecific antibody of any one of claims 1-4, wherein the detuned anti-HSA antibody region is N-terminal to the first target-specific antibody region.

6. The bispecific antibody of any one of claims 1-4, wherein the detuned anti-HSA antibody region is C-terminal to the first target-specific antibody region.

7. The bispecific antibody of any one of claims 2-6, wherein the detuned anti-HSA antibody region comprises one or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

8. The bispecific antibody of any one of claims 2-7, wherein the detuned anti-HSA antibody region comprises two or more mutations, three or more mutations, four or more mutations, five or more mutations, six or more mutations, seven or more mutations, eight or more mutations, nine or more mutations, or ten or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

9. The bispecific antibody of any one of claims 2-8, wherein the detuned anti-HSA antibody region comprises a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49.

10. The bispecific antibody of any one of claims 2-9, wherein the detuned anti-HSA antibody region provides the bispecific antibody increased stability, e.g., ’ / z life, when compared to an equivalent bispecific antibody lacking the detuned anti-HSA antibody region.

11. The bispecific antibody of any one of claims 2-10, wherein the detuned anti-HSA antibody region provides increased accessibility to a synapse between cells compared to an equivalent bispecific antibody comprising a wild type anti-HSA antibody region062460-505001WG 12. The bispecific antibody of claim 11, wherein the increased accessibility to the synapse between cells improves activity of the bispecific antibody.

13. The bispecific antibody of any one of claims 2-12, wherein the bispecific antibody comprises two or more detuned anti-HSA antibody regions and / or two or more first target-specific antibody regions.

14. The bispecific antibody of any one of claims 2-13, wherein the bispecific antibody comprises two detuned anti-HSA antibody regions and one first target-specific antibody region.

15. The bispecific antibody of any one of claims 2-13, wherein the bispecific antibody comprises one detuned anti-HSA antibody regions and two first target-specific antibody regions.

16. The bispecific antibody of any one of claims 1-15, wherein the bispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 226 (GFTFSSFG), SEQ ID NO: 227 (ISGSGSDT), and SEQ ID NO: 228 (TIGGGLSR) respectively.

17. The bispecific antibody of any one of claims 1-15, wherein the bispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 229 (GFTFRSFG), SEQ ID NO: 230 (ISGSGSDT), and SEQ ID NO: 231 (TISGSLSR) respectively.

18. The bispecific antibody of any one of claims 1-15, wherein the bispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 232 (GFTFRSFG), SEQ ID NO: 233 (ISGSGSDT), and SEQ ID NO: 234 (TIGGVLSR) respectively.

19. The bispecific antibody of any one of claims 1-15, wherein the bispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 235 (GFTFSSFG), SEQ ID NO: 236 (ISGSGSDT), and SEQ ID NO: 237 (GGGLSR) respectively.

20. The bispecific antibody of any one of claims 1-19, further comprising a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 57 and a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 58 or 59.

21. The bispecific antibody of any one of claims 1-20, wherein the first target-specific antibody region is directed to a cancer-related epitope.

22. The bispecific antibody of any one of claims 1-21, wherein the first target-specific antibody region is directed to an immune cell related epitope.062460-505001WG 23. The bispecific antibody of claim 22, wherein the immune cell-related epitope is relevant to an autoimmune disease or an inflammatory disease.

24. The bispecific antibody of any one of claims 22-23, wherein the autoimmune diseases or the inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

25. The bispecific antibody of any one of claims 22-23, wherein the autoimmune disease or the inflammatory disease is a graft-versus-host disease (GVHD).

26. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease, the method comprising contacting an effector cell with an effective amount of the bispecific antibody of any one of claims 1 to 20.

27. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject in need thereof, the method comprising contacting an effector cell with an effective amount of the bispecific antibody of any one of claims 1 to 20.

28. The method of claim 26-27, wherein the effector cell is in vitro, ex vivo, or in vivo.

29. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject, the method comprising administering to the subject an effective amount of the bispecific antibody of any one of claims 1 to 20.

30. The method of any one of claims 26-29, wherein the autoimmune diseases or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

31. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD), the method comprising contacting an effector cell with an effective amount of the bispecific antibody of any one of claims 1 to 20.

32. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject in need thereof, the method comprising contacting an effector cell with an effective amount of the bispecific antibody of any one of claims 1 to 20.

33. The method of claims 31-32, wherein the effector cell is in vitro, ex vivo, or in vivo.

34. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject an effective amount of the bispecific antibody of any one of claims 1 to 20.062460-505001WG 35. The method of claims 26-34, further comprising administering to the subject an effective amount of an immunomodulatory drug.

36. The method of claim 35, wherein the immunomodulatory drug is a checkpoint inhibitor, adoptive T cell therapy, monoclonal antibody therapy, corticosteroid, tumor necrosis factor inhibitor, interleukin-1 (IL-1) inhibitor, interleukin-6 (IL-6) inhibitor, T cell inhibitor, B-cell inhibitor, or Janus Kinase inhibitor.

37. The method of claims 35-36, wherein the immunomodulatory drug is an immunosuppressant.

38. The method of any one of claims 35-37, further comprising administering an effective amount of a standard of care therapy.

39. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1 to 20 and a pharmaceutically acceptable carrier, diluent, or excipient.

40. The pharmaceutical composition of claim 39, for use as a medicament in the treatment of an autoimmune disease or inflammatory disease or in the treatment of a graft-versus-host disease (GVHD).

41. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 39-40.

42. The method of claim 41, wherein the autoimmune diseases or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

43. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 39-40.

44. The method of claims 41-43, further comprising administering to the subject an effective amount of an immunomodulatory drug.

45. The method of claim 44, wherein the immunomodulatory drug is a checkpoint inhibitor, adoptive T cell therapy, monoclonal antibody therapy, corticosteroid, tumor necrosis factor inhibitor, interleukin-1 (IL-1) inhibitor, interleukin-6 (IL-6) inhibitor, T cell inhibitor, B-cell inhibitor, or Janus Kinase inhibitor.

46. The method of claims 44-45, wherein the immunomodulatory drug is an immunosuppressant.

47. The method of any one of claims 44-46, further comprising administering an effective amount of a standard of care therapy.062460-505001WG 48. A polynucleotide or plurality of polynucleotides encoding the bispecific antibody of any one of claims 1 to 20.

49. A vector comprising the polynucleotide or plurality of polynucleotides of claim 48.

50. A trispecific antibody comprising a detuned Human Serum Albumin (HSA) antibody region, a first target-specific antibody region, and a second target-specific antibody region.

51. The trispecific antibody of claim 50, wherein the detuned anti-HSA antibody region the first target-specific antibody region, and the second target-specific antibody region are each variable domains on a heavy chain (VHH).

52. The trispecific antibody of any one of claims 50-51, wherein the detuned anti-HSA antibody region, the first target-specific antibody region, and the second target-specific antibody region are serially linked.

53. The trispecific antibody of any one of claims 50-52, wherein the detuned anti-HSA antibody region and the first target-specific antibody region are serially linked via a linker.

54. The trispecific antibody of any one of claims 50-53, wherein the detuned anti-HSA antibody region and the second target-specific antibody region are serially linked via a linker.

55. The trispecific antibody of any one of claims 50-54, wherein the first target-specific antibody region and the second target-specific antibody region are serially linked via a linker.

56. The trispecific antibody of any one of claims 50-55, wherein the detuned anti-HSA antibody region is C-terminal to the first target-specific antibody region and / or to the second target-specific antibody region.

57. The trispecific antibody of any one of claims 50-56, wherein the detuned anti-HSA antibody region is N-terminal to the first target-specific antibody region and / or to the second targetspecific antibody region.

58. The trispecific antibody of any one of claims 50-57, wherein the first target-specific antibody region is N-terminal to the to the second target-specific antibody region.

59. The trispecific antibody of any one of claims 50-57, wherein the first target-specific antibody region is C-terminal to the to the second target-specific antibody region.

60. The trispecific antibody of any one of claims 51-59, wherein the detuned anti-HSA antibody region comprises one or more mutations relative to a wild type anti-HSA VHH (e g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

61. The trispecific antibody of any one of claims 51-60, wherein the detuned anti-HSA antibody region comprises two or more mutations, three or more mutations, four or more mutations, five or more mutations, six or more mutations, seven or more mutations, eight or more mutations, nine or062460-505001WG more mutations, or ten or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

62. The trispecific antibody of any one of claims 51-61 wherein the detuned anti-HSA antibody region provides the trispecific antibody increased stability, e.g., ’A life, when compared to an equivalent trispecific antibody lacking the detuned anti-HSA antibody region.

63. The trispecific antibody of any one of claims 51-62, wherein the detuned anti-HSA antibody region provides increased accessibility to a synapse between cells compared to an equivalent trispecific antibody comprising a wild type anti-HSA antibody region64. The trispecific antibody of claim 63, wherein the increased accessibility to the synapse between cells improves activity of the trispecific antibody.

65. The trispecific antibody of any one of claims 51-63, wherein the detuned anti-HSA antibody region comprises a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49.

66. The trispecific antibody of any one of claims 50-65, wherein the trispecific antibody comprises two or more detuned anti-HSA antibody regions and / or two or more first target-specific antibody regions and / or two or more second target-specific antibody regions.

67. The trispecific antibody of any one of claims 50-66, wherein the trispecific antibody comprises two detuned anti-HSA antibody regions and one first target-specific antibody region and one second target-specific antibody region.

68. The trispecific antibody of any one of claims 50-66, wherein the trispecific antibody comprises one detuned anti-HSA antibody regions and one first target-specific antibody region and two second target-specific antibody regions.

69. The trispecific antibody of any one of claims 50-66, wherein the trispecific antibody comprises one detuned anti-HSA antibody regions and two first target-specific antibody region and two second target-specific antibody regions.

70. The trispecific antibody of any one of claims 50-66, wherein the trispecific antibody comprises two detuned anti-HSA antibody regions and two first target-specific antibody region and one second target-specific antibody regions.

71. The trispecific antibody of any one of claims 50-70, wherein the trispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 226 (GFTFSSFG), SEQ ID NO: 227 (ISGSGSDT), and SEQ ID NO: 228 (TIGGGLSR) respectively.062460-505001WG 72. The trispecific antibody of any one of claims 50-70, wherein the trispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 229 (GFTFRSFG), SEQ ID NO: 230 (ISGSGSDT), and SEQ ID NO: 231 (TISGSLSR) respectively.

73. The trispecific antibody of any one of claims 50-70, wherein the trispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 232 (GFTFRSFG), SEQ ID NO: 233 (ISGSGSDT), and SEQ ID NO: 234 (TIGGVLSR) respectively.

74. The trispecific antibody of any one of claims 50-70, wherein the trispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 235 (GFTFSSFG), SEQ ID NO: 236 (ISGSGSDT), and SEQ ID NO: 237 (GGGLSR) respectively.

75. The trispecific antibody of any one of claims 50-74, further comprising a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 57 and a constant region that is at least 90%o identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 58 or 59.

76. The trispecific antibody of any one of claims 50-75, wherein the first target-specific antibody region and / or the second target-specific antibody region is directed to an immune cell related epitope.

77. The trispecific antibody of claim 76, wherein the immune cell-related epitope is relevant to an autoimmune disease or an inflammatory disease.

78. The trispecific antibody of any one of claims 76-77, wherein the autoimmune diseases or the inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

79. The trispecific antibody of any one of claims 76-77, wherein the autoimmune disease or the inflammatory disease is a graft-versus-host disease (GVHD).

80. The trispecific antibody of any one of claims 50-75, wherein the first target-specific antibody region is directed to a cancer-related epitope and / or the second target-specific antibody region is directed to a cancer-related epitope.062460-505001WG 81. The trispecific antibody of claim 80, wherein the first target-specific antibody region binds to an antigen expressed by a cancer cell and the second target-specific antibody region binds to antigen expressed by the cancer cell.

82. The trispecific antibody of claim 80, wherein the first target-specific antibody region binds to an antigen expressed by a cancer cell and the second target-specific antibody region binds to an antigen expressed by an effector cell.

83. The trispecific antibody of claim 80, wherein the first target-specific antibody region binds to an antigen expressed by an effector cell and the second target-specific antibody region binds to an antigen expressed by the effector cell.

84. The trispecific antibody of any one of claims 82-83, wherein the effector cell is a CD8+ T cell (e.g., a CD8+ CD4- T cell), a CD4+ T cell (e.g., a CD8- CD4+ T cell), a gamma delta (y8) T cell, an invariant T cell, a natural killer (NK) cell, an invariant natural killer cell (iNK cell), an invariant natural killer T cell (iNKT cell), or a macrophage.

85. The trispecific antibody of any one of claims 82-84, wherein the effector cell is a T cell.

86. The trispecific antibody of claim 85, wherein the T cell is a CD4+ T cell or a CD8+ T cell.

87. The trispecific antibody of any one of claims 82-86, wherein binding of the trispecific antibody to antigens on the effector cell promotes recruitment of protein complexes to an immunological synapse.

88. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease, the method comprising contacting an effector cell with an effective amount of the trispecific antibody of any one of claims 50 to 70.

89. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject in need thereof, the method comprising contacting an effector cell with an effective amount of the trispecific antibody of any one of claims 50 to 65.

90. The method of any one of claims 88-89, wherein the effector cell is in vitro, ex vivo, or in vivo.

91. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject, the method comprising administering to the subject an effective amount of the trispecific antibody of any one of claims 50 to 65.

92. The method of any one of claims 88-91, wherein the autoimmune diseases or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).062460-505001WG 93. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD), the method comprising contacting an effector cell with an effective amount of the trispecific antibody of any one of claims 50 to 65.

94. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject in need thereof, the method comprising contacting an effector cell with an effective amount of the trispecific antibody of any one of claims 50 to 65.

95. The method of claims 93-94, wherein the effector cell is in vitro, ex vivo, or in vivo.

96. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject an effective amount of the trispecific antibody of any one of claims 50 to 65.

97. The method of claims 88-96, further comprising administering to the subject an effective amount of an immunomodulatory drug.

98. The method of claim 97, wherein the immunomodulatory drug is a checkpoint inhibitor, adoptive T cell therapy, monoclonal antibody therapy, corticosteroid, tumor necrosis factor inhibitor, interleukin-1 (IL-1) inhibitor, interleukin-6 (IL-6) inhibitor, T cell inhibitor, B-cell inhibitor, or Janus Kinase inhibitor.

99. The method of claims 97-98, wherein the immunomodulatory drug is an immunosuppressant.

100. The method of any one of claims 97-99, further comprising administering an effective amount of a standard of care therapy.

101. A pharmaceutical composition comprising the trispecific antibody of any one of claims 50 to 65 and a pharmaceutically acceptable carrier, diluent, or excipient.

102. The pharmaceutical composition of claim 101, for use as a medicament in the treatment of an autoimmune disease or inflammatory disease or in the treatment of a graft-versus-host disease (GVHD).

103. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 101-102.

104. The method of claim 103, wherein the autoimmune diseases or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).062460-505001WG 105. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 101-102.

106. The method of claims 103-105, further comprising administering to the subject an effective amount of an immunomodulatory drug.

107. The method of claim 106, wherein the immunomodulatory drug is a checkpoint inhibitor, adoptive T cell therapy, monoclonal antibody therapy, corticosteroid, tumor necrosis factor inhibitor, interleukin-1 (IL-1) inhibitor, interleukin-6 (IL-6) inhibitor, T cell inhibitor, B-cell inhibitor, or Janus Kinase inhibitor.

108. The method of claims 106-107, wherein the immunomodulatory drug is an immunosuppressant.

109. The method of any one of claims 106-108, further comprising administering an effective amount of a standard of care therapy.

110. A polynucleotide or plurality of polynucleotides encoding the tri specific antibody of any one of claims 50 to 65.

111. A vector comprising the polynucleotide or plurality of polynucleotides of claim 110.

112. A multispecific antibody comprising a detuned Human Serum Albumin (HSA) antibody region, a first target-specific antibody region, and a second target-specific antibody region, and an at least third target-specific antibody region.

113. The multispecific antibody of claim 112, wherein the detuned anti-HSA antibody region the first target-specific antibody region, the second target-specific antibody region, and the at least third target-specific antibody region are each variable domains on a heavy chain (VHH).

114. The multispecific antibody of any one of claims 112-113, wherein the detuned anti-HSA antibody region, the first target-specific antibody region, the second target-specific antibody region, and the at least third target specific antibody region are serially linked.

115. The multispecific antibody of any one of claims 112-114, wherein the detuned anti-HSA antibody region, the first target-specific antibody region, the second target-specific antibody region, and / or the at least third target specific antibody region are serially linked via a linker.

116. The multispecific antibody of any one of claims 112-115, wherein the detuned anti-HSA antibody region is C-terminal to the first target-specific antibody region, to the second targetspecific antibody region, and / or the at least third target specific antibody region.062460-505001WG 117. The multispecific antibody of any one of claims 112-116, wherein the detuned anti-HSA antibody region is N-terminal to the first target-specific antibody region, to the second targetspecific antibody region, and / or the at least third target specific antibody region.

118. The multispecific antibody of any one of claims 113-117, wherein the detuned anti-HSA antibody region comprises one or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

119. The multispecific antibody of any one of claims 113-118, wherein the detuned anti-HSA antibody region comprises two or more mutations, three or more mutations, four or more mutations, five or more mutations, six or more mutations, seven or more mutations, eight or more mutations, nine or more mutations, or ten or more mutations relative to a wild type anti-HSA VHH (e.g., SEQ ID NO: 1) such that the detuned anti-HSA antibody region has reduced affinity to HSA.

120. The multispecific antibody of any one of claims 113-119, wherein the detuned anti-HSA antibody region provides increased accessibility to a synapse between cells compared to an equivalent multispecific antibody comprising a wild type anti-HSA antibody region121. The multispecific antibody of claim 120, wherein the increased accessibility to the synapse between cells improves activity of the multispecific antibody.

122. The multispecific antibody of any one of claims 113-121, wherein the detuned anti-HSA antibody region comprises a sequence that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 2 to 49.

123. The multispecific antibody of any one of claims 113-122, wherein the detuned anti-HSA antibody region provides the multispecific antibody increased stability, e.g., Y life, when compared to an equivalent multi specific antibody lacking the detuned anti-HSA antibody region.

124. The multispecific antibody of any one of claims 113-123, wherein the multispecific antibody comprises two or more detuned anti-HSA antibody regions and / or two or more first targetspecific antibody regions and / or two or more second target-specific antibody regions and / or two or more at least third second target-specific antibody regions.

125. The multispecific antibody of any one of claims 113-124, wherein the multispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 226 (GFTFSSFG), SEQ ID NO: 227 (ISGSGSDT), and SEQ ID NO: 228 (TIGGGLSR) respectively.

126. The multispecific antibody of any one of claims 113-124, wherein the multispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising062460-505001WG SEQ ID NO: 229 (GFTFRSFG), SEQ ID NO: 230 (ISGSGSDT), and SEQ ID NO: 231 (TISGSLSR) respectively.

127. The multispecific antibody of any one of claims 113-124, wherein the multispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 232 (GFTFRSFG), SEQ ID NO: 233 (ISGSGSDT), and SEQ ID NO: 234 (TIGGVLSR) respectively.

128. The multispecific antibody of any one of claims 113-124, wherein the multispecific comprises three Heavy Chain CDRs (CDR-H1, CDR-H2, and CDR-H3) for the anti-HSA region comprising SEQ ID NO: 235 (GFTFSSFG), SEQ ID NO: 236 (ISGSGSDT), and SEQ ID NO: 237 (GGGLSR) respectively.

129. The multispecific antibody of any one of claims 113-128, further comprising a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to SEQ ID NO: 57 and a constant region that is at least 90% identical (e.g., 95%, 99%, or 100% identical) to one of SEQ ID NO: 58 or 59.

130. The multispecific antibody of any one of claims 112-129, wherein the first target-specific antibody region and / or the second target-specific antibody region is directed to an immune cell related epitope.

131. The multispecific antibody of claim 130, wherein the immune cell-related epitope is relevant to an autoimmune disease or an inflammatory disease.

132. The multispecific antibody of any one of claims 130-131, wherein the autoimmune diseases or the inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).

133. The multispecific antibody of any one of claims 130-131, wherein the autoimmune disease or the inflammatory disease is a graft-versus-host disease (GVHD).

134. The multispecific antibody of any one of claims 112-129, wherein the first target-specific antibody region is directed to a cancer-related epitope and / or the second target-specific antibody region is directed to a cancer-related epitope.

135. The multispecific antibody of claim 134, wherein the first target-specific antibody region binds to an antigen expressed by a cancer cell and / or the second target-specific antibody region binds to antigen expressed by the cancer cell and / or the at least third target-specific antibody region binds to antigen expressed by the cancer cell.062460-505001WG 136. The multispecific antibody of claim 134, wherein the first target-specific antibody region binds to an antigen expressed by a cancer cell or an effector cell and / or the second target-specific antibody region binds to antigen expressed by the cancer cell or the effector cell and / or the at least third target-specific antibody region binds to antigen expressed by the a cancer cell or the effector cell.

137. The multispecific antibody of claim 134, wherein the first target-specific antibody region binds to an antigen expressed by an effector cell and the second target-specific antibody region binds to an antigen expressed by the effector cell.

138. The multispecific antibody of any one of claims 136-137, wherein the effector cell is a CD8+ T cell (e.g., a CD8+ CD4- T cell), a CD4+ T cell (e.g., a CD8- CD4+ T cell), a gamma delta (y5) T cell, an invariant T cell, a natural killer (NK) cell, an invariant natural killer cell (iNK cell), an invariant natural killer T cell (iNKT cell), or a macrophage.

139. The multispecific antibody of any one of claims 136-138, wherein the effector cell is a T cell.

140. The multispecific antibody of claim 139, wherein the T cell is a CD4+ T cell or a CD8+ T cell.

141. The multispecific antibody of any one of claims 136-140, wherein binding of the multispecific antibody to antigens on the effector cell promotes recruitment of protein complexes to an immunological synapse.

142. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease, the method comprising contacting an effector cell with an effective amount of the multispecific antibody of any one of claims 112 to 129.

143. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject in need thereof, the method comprising contacting an effector cell with an effective amount of the multispecific antibody of any one of claims 112 to 129.

144. The method of any one of claims 142-143, wherein the effector cell is in vitro, ex vivo, or in vivo.

145. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject, the method comprising administering to the subject an effective amount of the multispecific antibody of any one of claims 112 to 129.

146. The method of any one of claims 142-145, wherein the autoimmune diseases or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).062460-505001WG 147. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD), the method comprising contacting an effector cell with an effective amount of the multispecific antibody of any one of claims 112 to 129.

148. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject in need thereof, the method comprising contacting an effector cell with an effective amount of the multispecific antibody of any one of claims 112 to 129.

149. The method of claims 147-148, wherein the effector cell is in vitro, ex vivo, or in vivo.

150. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject an effective amount of the multispecific antibody of any one of claims 112 to 129.

151. The method of claims 142-150, further comprising administering to the subject an effective amount of an immunomodulatory drug.

152. The method of claim 151, wherein the immunomodulatory drug is a checkpoint inhibitor, adoptive T cell therapy, monoclonal antibody therapy, corticosteroid, tumor necrosis factor inhibitor, interleukin-1 (IL-1) inhibitor, interleukin-6 (IL-6) inhibitor, T cell inhibitor, B-cell inhibitor, or Janus Kinase inhibitor.

153. The method of claims 151-152, wherein the immunomodulatory drug is an immunosuppressant.

154. The method of any one of claims 151-153, further comprising administering an effective amount of a standard of care therapy.

155. A pharmaceutical composition comprising the multispecific antibody of any one of claims 112 to 129 and a pharmaceutically acceptable carrier, diluent, or excipient.

156. The pharmaceutical composition of claim 155, for use as a medicament in the treatment of an autoimmune disease or inflammatory disease or in the treatment of a graft-versus-host disease (GVHD).

157. A method of treating, preventing, or reducing the severity of an autoimmune disease or inflammatory disease in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 155-156.

158. The method of claim 157, wherein the autoimmune diseases or inflammatory disease is Type 1 diabetes (T1D), Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE), Myasthenia gravis (MG), Autoimmune uveitis (AU), Sjogren's syndrome (SjS), Inflammatory bowel diseases (IBD), or Autoimmune hepatitis (AIH), Behcet's disease (BD).062460-505001WG 159. A method of treating, preventing, or reducing the severity of a graft-versus-host disease (GVHD) in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 155-156.

160. The method of claims 157-159, further comprising administering to the subject an effective amount of an immunomodulatory drug.

161. The method of claim 160, wherein the immunomodulatory drug is a checkpoint inhibitor, adoptive T cell therapy, monoclonal antibody therapy, corticosteroid, tumor necrosis factor inhibitor, interleukin-1 (IL-1) inhibitor, interleukin-6 (IL-6) inhibitor, T cell inhibitor, B-cell inhibitor, or Janus Kinase inhibitor.

162. The method of claims 160-161, wherein the immunomodulatory drug is an immunosuppressant.

163. The method of any one of claims 160-162, further comprising administering an effective amount of a standard of care therapy.

164. A polynucleotide or plurality of polynucleotides encoding the multispecific antibody of any one of claims 112 to 129.

165. A vector comprising the polynucleotide or plurality of polynucleotides of claim 164.